id	sid	tid	token	lemma	pos
cord-268347-xz6fptol	1	1	key	key	NN
cord-268347-xz6fptol	1	2	:	:	:
cord-268347-xz6fptol	2	1	cord-268347-xz6fptol	cord-268347-xz6fptol	XX
cord-268347-xz6fptol	3	1	authors	author	NNS
cord-268347-xz6fptol	3	2	:	:	:
cord-268347-xz6fptol	3	3	Kow	Kow	NNP
cord-268347-xz6fptol	3	4	,	,	,
cord-268347-xz6fptol	3	5	Chia	Chia	NNP
cord-268347-xz6fptol	3	6	Siang	Siang	NNP
cord-268347-xz6fptol	3	7	;	;	:
cord-268347-xz6fptol	3	8	Hasan	Hasan	NNP
cord-268347-xz6fptol	3	9	,	,	,
cord-268347-xz6fptol	3	10	Syed	Syed	NNP
cord-268347-xz6fptol	3	11	Shahzad	Shahzad	NNP
cord-268347-xz6fptol	4	1	title	title	NN
cord-268347-xz6fptol	4	2	:	:	:
cord-268347-xz6fptol	4	3	Pharmacotherapeutic	pharmacotherapeutic	JJ
cord-268347-xz6fptol	4	4	considerations	consideration	NNS
cord-268347-xz6fptol	4	5	for	for	IN
cord-268347-xz6fptol	4	6	systemic	systemic	JJ
cord-268347-xz6fptol	4	7	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	4	8	diseases	disease	NNS
cord-268347-xz6fptol	4	9	amid	amid	IN
cord-268347-xz6fptol	4	10	the	the	DT
cord-268347-xz6fptol	4	11	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	4	12	pandemic	pandemic	NN
cord-268347-xz6fptol	4	13	:	:	:
cord-268347-xz6fptol	4	14	more	more	JJR
cord-268347-xz6fptol	4	15	questions	question	NNS
cord-268347-xz6fptol	4	16	than	than	IN
cord-268347-xz6fptol	4	17	answers	answer	NNS
cord-268347-xz6fptol	4	18	date	date	NN
cord-268347-xz6fptol	4	19	:	:	:
cord-268347-xz6fptol	4	20	2020	2020	CD
cord-268347-xz6fptol	4	21	-	-	HYPH
cord-268347-xz6fptol	4	22	08	08	CD
cord-268347-xz6fptol	4	23	-	-	SYM
cord-268347-xz6fptol	4	24	16	16	CD
cord-268347-xz6fptol	4	25	journal	journal	NN
cord-268347-xz6fptol	4	26	:	:	:
cord-268347-xz6fptol	5	1	Drugs	drug	NNS
cord-268347-xz6fptol	6	1	Ther	Ther	NNP
cord-268347-xz6fptol	6	2	Perspect	Perspect	NNP
cord-268347-xz6fptol	6	3	DOI	DOI	NNP
cord-268347-xz6fptol	6	4	:	:	:
cord-268347-xz6fptol	6	5	10.1007	10.1007	CD
cord-268347-xz6fptol	6	6	/	/	SYM
cord-268347-xz6fptol	6	7	s40267	s40267	CD
cord-268347-xz6fptol	6	8	-	-	HYPH
cord-268347-xz6fptol	6	9	020	020	CD
cord-268347-xz6fptol	6	10	-	-	HYPH
cord-268347-xz6fptol	6	11	00767	00767	CD
cord-268347-xz6fptol	6	12	-	-	SYM
cord-268347-xz6fptol	6	13	1	1	CD
cord-268347-xz6fptol	6	14	sha	sha	NNP
cord-268347-xz6fptol	6	15	:	:	:
cord-268347-xz6fptol	7	1	d406a330dfc60bddd74a90b545fcd06b8fc78945	d406a330dfc60bddd74a90b545fcd06b8fc78945	NNP
cord-268347-xz6fptol	7	2	doc_id	doc_id	CD
cord-268347-xz6fptol	7	3	:	:	:
cord-268347-xz6fptol	7	4	268347	268347	CD
cord-268347-xz6fptol	7	5	cord_uid	cord_uid	NNS
cord-268347-xz6fptol	7	6	:	:	:
cord-268347-xz6fptol	7	7	xz6fptol	xz6fptol	ADD
cord-268347-xz6fptol	8	1	Thus	thus	RB
cord-268347-xz6fptol	8	2	far	far	RB
cord-268347-xz6fptol	8	3	,	,	,
cord-268347-xz6fptol	8	4	associations	association	NNS
cord-268347-xz6fptol	8	5	between	between	IN
cord-268347-xz6fptol	8	6	the	the	DT
cord-268347-xz6fptol	8	7	presence	presence	NN
cord-268347-xz6fptol	8	8	of	of	IN
cord-268347-xz6fptol	8	9	systemic	systemic	JJ
cord-268347-xz6fptol	8	10	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	8	11	disease	disease	NN
cord-268347-xz6fptol	8	12	and	and	CC
cord-268347-xz6fptol	8	13	an	an	DT
cord-268347-xz6fptol	8	14	increased	increase	VBN
cord-268347-xz6fptol	8	15	risk	risk	NN
cord-268347-xz6fptol	8	16	of	of	IN
cord-268347-xz6fptol	8	17	novel	novel	JJ
cord-268347-xz6fptol	8	18	coronavirus	coronavirus	NN
cord-268347-xz6fptol	8	19	disease	disease	NN
cord-268347-xz6fptol	8	20	2019	2019	CD
cord-268347-xz6fptol	8	21	(	(	-LRB-
cord-268347-xz6fptol	8	22	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	8	23	)	)	-RRB-
cord-268347-xz6fptol	8	24	acquisition	acquisition	NN
cord-268347-xz6fptol	8	25	or	or	CC
cord-268347-xz6fptol	8	26	a	a	DT
cord-268347-xz6fptol	8	27	worse	bad	JJR
cord-268347-xz6fptol	8	28	prognosis	prognosis	NN
cord-268347-xz6fptol	8	29	from	from	IN
cord-268347-xz6fptol	8	30	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	8	31	have	have	VBP
cord-268347-xz6fptol	8	32	not	not	RB
cord-268347-xz6fptol	8	33	been	be	VBN
cord-268347-xz6fptol	8	34	conclusive	conclusive	JJ
cord-268347-xz6fptol	8	35	.	.	.
cord-268347-xz6fptol	9	1	It	-PRON-	PRP
cord-268347-xz6fptol	9	2	is	be	VBZ
cord-268347-xz6fptol	9	3	not	not	RB
cord-268347-xz6fptol	9	4	known	know	VBN
cord-268347-xz6fptol	9	5	for	for	IN
cord-268347-xz6fptol	9	6	certain	certain	JJ
cord-268347-xz6fptol	9	7	if	if	IN
cord-268347-xz6fptol	9	8	there	there	EX
cord-268347-xz6fptol	9	9	is	be	VBZ
cord-268347-xz6fptol	9	10	an	an	DT
cord-268347-xz6fptol	9	11	association	association	NN
cord-268347-xz6fptol	9	12	between	between	IN
cord-268347-xz6fptol	9	13	any	any	DT
cord-268347-xz6fptol	9	14	pharmacological	pharmacological	JJ
cord-268347-xz6fptol	9	15	agent	agent	NN
cord-268347-xz6fptol	9	16	used	use	VBN
cord-268347-xz6fptol	9	17	for	for	IN
cord-268347-xz6fptol	9	18	rheumatologic	rheumatologic	JJ
cord-268347-xz6fptol	9	19	treatment	treatment	NN
cord-268347-xz6fptol	9	20	,	,	,
cord-268347-xz6fptol	9	21	including	include	VBG
cord-268347-xz6fptol	9	22	biological	biological	JJ
cord-268347-xz6fptol	9	23	and	and	CC
cord-268347-xz6fptol	9	24	non	non	JJ
cord-268347-xz6fptol	9	25	-	-	JJ
cord-268347-xz6fptol	9	26	biological	biological	JJ
cord-268347-xz6fptol	9	27	disease	disease	NN
cord-268347-xz6fptol	9	28	-	-	HYPH
cord-268347-xz6fptol	9	29	modifying	modify	VBG
cord-268347-xz6fptol	9	30	antirheumatic	antirheumatic	JJ
cord-268347-xz6fptol	9	31	drugs	drug	NNS
cord-268347-xz6fptol	9	32	(	(	-LRB-
cord-268347-xz6fptol	9	33	DMARDs	dmard	NNS
cord-268347-xz6fptol	9	34	)	)	-RRB-
cord-268347-xz6fptol	9	35	,	,	,
cord-268347-xz6fptol	9	36	and	and	CC
cord-268347-xz6fptol	9	37	an	an	DT
cord-268347-xz6fptol	9	38	increased	increase	VBN
cord-268347-xz6fptol	9	39	risk	risk	NN
cord-268347-xz6fptol	9	40	of	of	IN
cord-268347-xz6fptol	9	41	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	9	42	acquisition	acquisition	NN
cord-268347-xz6fptol	9	43	or	or	CC
cord-268347-xz6fptol	9	44	adverse	adverse	JJ
cord-268347-xz6fptol	9	45	outcomes	outcome	NNS
cord-268347-xz6fptol	9	46	from	from	IN
cord-268347-xz6fptol	9	47	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	9	48	,	,	,
cord-268347-xz6fptol	9	49	although	although	IN
cord-268347-xz6fptol	9	50	these	these	DT
cord-268347-xz6fptol	9	51	agents	agent	NNS
cord-268347-xz6fptol	9	52	have	have	VBP
cord-268347-xz6fptol	9	53	been	be	VBN
cord-268347-xz6fptol	9	54	associated	associate	VBN
cord-268347-xz6fptol	9	55	with	with	IN
cord-268347-xz6fptol	9	56	an	an	DT
cord-268347-xz6fptol	9	57	overall	overall	JJ
cord-268347-xz6fptol	9	58	higher	high	JJR
cord-268347-xz6fptol	9	59	risk	risk	NN
cord-268347-xz6fptol	9	60	of	of	IN
cord-268347-xz6fptol	9	61	infections	infection	NNS
cord-268347-xz6fptol	9	62	.	.	.
cord-268347-xz6fptol	10	1	The	the	DT
cord-268347-xz6fptol	10	2	pharmacological	pharmacological	JJ
cord-268347-xz6fptol	10	3	management	management	NN
cord-268347-xz6fptol	10	4	of	of	IN
cord-268347-xz6fptol	10	5	patients	patient	NNS
cord-268347-xz6fptol	10	6	with	with	IN
cord-268347-xz6fptol	10	7	a	a	DT
cord-268347-xz6fptol	10	8	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	10	9	disease	disease	NN
cord-268347-xz6fptol	10	10	without	without	IN
cord-268347-xz6fptol	10	11	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	10	12	should	should	MD
cord-268347-xz6fptol	10	13	currently	currently	RB
cord-268347-xz6fptol	10	14	follow	follow	VB
cord-268347-xz6fptol	10	15	usual	usual	JJ
cord-268347-xz6fptol	10	16	treatment	treatment	NN
cord-268347-xz6fptol	10	17	approaches	approach	NNS
cord-268347-xz6fptol	10	18	.	.	.
cord-268347-xz6fptol	11	1	Individualized	individualized	JJ
cord-268347-xz6fptol	11	2	approaches	approach	NNS
cord-268347-xz6fptol	11	3	to	to	IN
cord-268347-xz6fptol	11	4	adjusting	adjust	VBG
cord-268347-xz6fptol	11	5	DMARD	DMARD	NNP
cord-268347-xz6fptol	11	6	regimens	regimen	NNS
cord-268347-xz6fptol	11	7	in	in	IN
cord-268347-xz6fptol	11	8	patients	patient	NNS
cord-268347-xz6fptol	11	9	with	with	IN
cord-268347-xz6fptol	11	10	documented	document	VBN
cord-268347-xz6fptol	11	11	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	11	12	seems	seem	VBZ
cord-268347-xz6fptol	11	13	prudent	prudent	JJ
cord-268347-xz6fptol	11	14	,	,	,
cord-268347-xz6fptol	11	15	with	with	IN
cord-268347-xz6fptol	11	16	specific	specific	JJ
cord-268347-xz6fptol	11	17	attention	attention	NN
cord-268347-xz6fptol	11	18	paid	pay	VBN
cord-268347-xz6fptol	11	19	to	to	IN
cord-268347-xz6fptol	11	20	the	the	DT
cord-268347-xz6fptol	11	21	severity	severity	NN
cord-268347-xz6fptol	11	22	of	of	IN
cord-268347-xz6fptol	11	23	the	the	DT
cord-268347-xz6fptol	11	24	infection	infection	NN
cord-268347-xz6fptol	11	25	.	.	.
cord-268347-xz6fptol	12	1	Patients	patient	NNS
cord-268347-xz6fptol	12	2	receiving	receive	VBG
cord-268347-xz6fptol	12	3	antimalarials	antimalarial	NNS
cord-268347-xz6fptol	12	4	(	(	-LRB-
cord-268347-xz6fptol	12	5	hydroxychloroquine	hydroxychloroquine	NNP
cord-268347-xz6fptol	12	6	/	/	SYM
cord-268347-xz6fptol	12	7	chloroquine	chloroquine	NN
cord-268347-xz6fptol	12	8	)	)	-RRB-
cord-268347-xz6fptol	12	9	may	may	MD
cord-268347-xz6fptol	12	10	continue	continue	VB
cord-268347-xz6fptol	12	11	treatment	treatment	NN
cord-268347-xz6fptol	12	12	with	with	IN
cord-268347-xz6fptol	12	13	these	these	DT
cord-268347-xz6fptol	12	14	agents	agent	NNS
cord-268347-xz6fptol	12	15	.	.	.
cord-268347-xz6fptol	13	1	Treatment	treatment	NN
cord-268347-xz6fptol	13	2	with	with	IN
cord-268347-xz6fptol	13	3	sulfasalazine	sulfasalazine	NN
cord-268347-xz6fptol	13	4	,	,	,
cord-268347-xz6fptol	13	5	methotrexate	methotrexate	NNP
cord-268347-xz6fptol	13	6	,	,	,
cord-268347-xz6fptol	13	7	leflunomide	leflunomide	NN
cord-268347-xz6fptol	13	8	,	,	,
cord-268347-xz6fptol	13	9	immunosuppressants	immunosuppressant	NNS
cord-268347-xz6fptol	13	10	and	and	CC
cord-268347-xz6fptol	13	11	biological	biological	JJ
cord-268347-xz6fptol	13	12	agents	agent	NNS
cord-268347-xz6fptol	13	13	other	other	JJ
cord-268347-xz6fptol	13	14	than	than	IN
cord-268347-xz6fptol	13	15	interluekin-6	interluekin-6	NNP
cord-268347-xz6fptol	13	16	receptor	receptor	NN
cord-268347-xz6fptol	13	17	inhibitors	inhibitor	NNS
cord-268347-xz6fptol	13	18	and	and	CC
cord-268347-xz6fptol	13	19	JAK	JAK	NNP
cord-268347-xz6fptol	13	20	inhibitors	inhibitor	NNS
cord-268347-xz6fptol	13	21	should	should	MD
cord-268347-xz6fptol	13	22	be	be	VB
cord-268347-xz6fptol	13	23	stopped	stop	VBN
cord-268347-xz6fptol	13	24	or	or	CC
cord-268347-xz6fptol	13	25	withheld	withhold	VBN
cord-268347-xz6fptol	13	26	.	.	.
cord-268347-xz6fptol	14	1	It	-PRON-	PRP
cord-268347-xz6fptol	14	2	should	should	MD
cord-268347-xz6fptol	14	3	be	be	VB
cord-268347-xz6fptol	14	4	reasonable	reasonable	JJ
cord-268347-xz6fptol	14	5	to	to	TO
cord-268347-xz6fptol	14	6	resume	resume	VB
cord-268347-xz6fptol	14	7	DMARD	DMARD	NNP
cord-268347-xz6fptol	14	8	treatment	treatment	NN
cord-268347-xz6fptol	14	9	when	when	WRB
cord-268347-xz6fptol	14	10	patients	patient	NNS
cord-268347-xz6fptol	14	11	are	be	VBP
cord-268347-xz6fptol	14	12	no	no	RB
cord-268347-xz6fptol	14	13	longer	long	RBR
cord-268347-xz6fptol	14	14	symptomatic	symptomatic	JJ
cord-268347-xz6fptol	14	15	and	and	CC
cord-268347-xz6fptol	14	16	at	at	IN
cord-268347-xz6fptol	14	17	least	least	JJS
cord-268347-xz6fptol	14	18	2	2	CD
cord-268347-xz6fptol	14	19	weeks	week	NNS
cord-268347-xz6fptol	14	20	after	after	IN
cord-268347-xz6fptol	14	21	documentation	documentation	NN
cord-268347-xz6fptol	14	22	of	of	IN
cord-268347-xz6fptol	14	23	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	14	24	,	,	,
cord-268347-xz6fptol	14	25	although	although	IN
cord-268347-xz6fptol	14	26	the	the	DT
cord-268347-xz6fptol	14	27	decision	decision	NN
cord-268347-xz6fptol	14	28	should	should	MD
cord-268347-xz6fptol	14	29	be	be	VB
cord-268347-xz6fptol	14	30	individualized	individualize	VBN
cord-268347-xz6fptol	14	31	,	,	,
cord-268347-xz6fptol	14	32	preferably	preferably	RB
cord-268347-xz6fptol	14	33	based	base	VBN
cord-268347-xz6fptol	14	34	on	on	IN
cord-268347-xz6fptol	14	35	infection	infection	NN
cord-268347-xz6fptol	14	36	severity	severity	NN
cord-268347-xz6fptol	14	37	.	.	.
cord-268347-xz6fptol	15	1	In	in	IN
cord-268347-xz6fptol	15	2	late	late	JJ
cord-268347-xz6fptol	15	3	2019	2019	CD
cord-268347-xz6fptol	15	4	,	,	,
cord-268347-xz6fptol	15	5	an	an	DT
cord-268347-xz6fptol	15	6	outbreak	outbreak	NN
cord-268347-xz6fptol	15	7	of	of	IN
cord-268347-xz6fptol	15	8	pneumonia	pneumonia	NN
cord-268347-xz6fptol	15	9	cases	case	NNS
cord-268347-xz6fptol	15	10	was	be	VBD
cord-268347-xz6fptol	15	11	reported	report	VBN
cord-268347-xz6fptol	15	12	in	in	IN
cord-268347-xz6fptol	15	13	Wuhan	Wuhan	NNP
cord-268347-xz6fptol	15	14	,	,	,
cord-268347-xz6fptol	15	15	a	a	DT
cord-268347-xz6fptol	15	16	city	city	NN
cord-268347-xz6fptol	15	17	in	in	IN
cord-268347-xz6fptol	15	18	the	the	DT
cord-268347-xz6fptol	15	19	Hubei	Hubei	NNP
cord-268347-xz6fptol	15	20	province	province	NN
cord-268347-xz6fptol	15	21	of	of	IN
cord-268347-xz6fptol	15	22	China	China	NNP
cord-268347-xz6fptol	15	23	,	,	,
cord-268347-xz6fptol	15	24	which	which	WDT
cord-268347-xz6fptol	15	25	has	have	VBZ
cord-268347-xz6fptol	15	26	later	later	RB
cord-268347-xz6fptol	15	27	been	be	VBN
cord-268347-xz6fptol	15	28	termed	term	VBN
cord-268347-xz6fptol	15	29	novel	novel	JJ
cord-268347-xz6fptol	15	30	coronavirus	coronavirus	NN
cord-268347-xz6fptol	15	31	disease	disease	NN
cord-268347-xz6fptol	15	32	2019	2019	CD
cord-268347-xz6fptol	16	1	(	(	-LRB-
cord-268347-xz6fptol	16	2	COVID-	COVID-	NNP
cord-268347-xz6fptol	16	3	19	19	CD
cord-268347-xz6fptol	16	4	)	)	-RRB-
cord-268347-xz6fptol	16	5	.	.	.
cord-268347-xz6fptol	17	1	By	by	IN
cord-268347-xz6fptol	17	2	2020	2020	CD
cord-268347-xz6fptol	17	3	,	,	,
cord-268347-xz6fptol	17	4	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	17	5	rapidly	rapidly	RB
cord-268347-xz6fptol	17	6	escalated	escalate	VBD
cord-268347-xz6fptol	17	7	to	to	IN
cord-268347-xz6fptol	17	8	a	a	DT
cord-268347-xz6fptol	17	9	pandemic	pandemic	NN
cord-268347-xz6fptol	17	10	that	that	WDT
cord-268347-xz6fptol	17	11	spread	spread	VBD
cord-268347-xz6fptol	17	12	to	to	IN
cord-268347-xz6fptol	17	13	almost	almost	RB
cord-268347-xz6fptol	17	14	all	all	DT
cord-268347-xz6fptol	17	15	countries	country	NNS
cord-268347-xz6fptol	17	16	in	in	IN
cord-268347-xz6fptol	17	17	the	the	DT
cord-268347-xz6fptol	17	18	world	world	NN
cord-268347-xz6fptol	17	19	.	.	.
cord-268347-xz6fptol	18	1	A	a	DT
cord-268347-xz6fptol	18	2	novel	novel	JJ
cord-268347-xz6fptol	18	3	coronavirus	coronavirus	NN
cord-268347-xz6fptol	18	4	,	,	,
cord-268347-xz6fptol	18	5	severe	severe	JJ
cord-268347-xz6fptol	18	6	acute	acute	JJ
cord-268347-xz6fptol	18	7	respiratory	respiratory	JJ
cord-268347-xz6fptol	18	8	syndrome	syndrome	NN
cord-268347-xz6fptol	18	9	coronavirus	coronavirus	NN
cord-268347-xz6fptol	18	10	2	2	CD
cord-268347-xz6fptol	18	11	(	(	-LRB-
cord-268347-xz6fptol	18	12	SARS	SARS	NNP
cord-268347-xz6fptol	18	13	-	-	HYPH
cord-268347-xz6fptol	18	14	CoV-2	CoV-2	NNP
cord-268347-xz6fptol	18	15	)	)	-RRB-
cord-268347-xz6fptol	18	16	,	,	,
cord-268347-xz6fptol	18	17	was	be	VBD
cord-268347-xz6fptol	18	18	identified	identify	VBN
cord-268347-xz6fptol	18	19	as	as	IN
cord-268347-xz6fptol	18	20	the	the	DT
cord-268347-xz6fptol	18	21	causeative	causeative	JJ
cord-268347-xz6fptol	18	22	pathogen	pathogen	NN
cord-268347-xz6fptol	18	23	of	of	IN
cord-268347-xz6fptol	18	24	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	18	25	.	.	.
cord-268347-xz6fptol	19	1	In	in	IN
cord-268347-xz6fptol	19	2	this	this	DT
cord-268347-xz6fptol	19	3	opinion	opinion	NN
cord-268347-xz6fptol	19	4	paper	paper	NN
cord-268347-xz6fptol	19	5	,	,	,
cord-268347-xz6fptol	19	6	we	-PRON-	PRP
cord-268347-xz6fptol	19	7	discuss	discuss	VBP
cord-268347-xz6fptol	19	8	the	the	DT
cord-268347-xz6fptol	19	9	pharmacotherapeutic	pharmacotherapeutic	JJ
cord-268347-xz6fptol	19	10	considerations	consideration	NNS
cord-268347-xz6fptol	19	11	of	of	IN
cord-268347-xz6fptol	19	12	patients	patient	NNS
cord-268347-xz6fptol	19	13	with	with	IN
cord-268347-xz6fptol	19	14	systemic	systemic	JJ
cord-268347-xz6fptol	19	15	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	19	16	diseases	disease	NNS
cord-268347-xz6fptol	19	17	during	during	IN
cord-268347-xz6fptol	19	18	the	the	DT
cord-268347-xz6fptol	19	19	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	19	20	pandemic	pandemic	NN
cord-268347-xz6fptol	19	21	based	base	VBN
cord-268347-xz6fptol	19	22	on	on	IN
cord-268347-xz6fptol	19	23	currently	currently	RB
cord-268347-xz6fptol	19	24	available	available	JJ
cord-268347-xz6fptol	19	25	evidence	evidence	NN
cord-268347-xz6fptol	19	26	(	(	-LRB-
cord-268347-xz6fptol	19	27	as	as	IN
cord-268347-xz6fptol	19	28	of	of	IN
cord-268347-xz6fptol	19	29	25	25	CD
cord-268347-xz6fptol	19	30	July	July	NNP
cord-268347-xz6fptol	19	31	2020	2020	CD
cord-268347-xz6fptol	19	32	)	)	-RRB-
cord-268347-xz6fptol	19	33	.	.	.
cord-268347-xz6fptol	20	1	Although	although	IN
cord-268347-xz6fptol	20	2	otherwise	otherwise	RB
cord-268347-xz6fptol	20	3	healthy	healthy	JJ
cord-268347-xz6fptol	20	4	individuals	individual	NNS
cord-268347-xz6fptol	20	5	can	can	MD
cord-268347-xz6fptol	20	6	acquire	acquire	VB
cord-268347-xz6fptol	20	7	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	20	8	or	or	CC
cord-268347-xz6fptol	20	9	develop	develop	VB
cord-268347-xz6fptol	20	10	a	a	DT
cord-268347-xz6fptol	20	11	severe	severe	JJ
cord-268347-xz6fptol	20	12	course	course	NN
cord-268347-xz6fptol	20	13	of	of	IN
cord-268347-xz6fptol	20	14	the	the	DT
cord-268347-xz6fptol	20	15	disease	disease	NN
cord-268347-xz6fptol	20	16	,	,	,
cord-268347-xz6fptol	20	17	it	-PRON-	PRP
cord-268347-xz6fptol	20	18	is	be	VBZ
cord-268347-xz6fptol	20	19	more	more	RBR
cord-268347-xz6fptol	20	20	likely	likely	JJ
cord-268347-xz6fptol	20	21	among	among	IN
cord-268347-xz6fptol	20	22	patients	patient	NNS
cord-268347-xz6fptol	20	23	with	with	IN
cord-268347-xz6fptol	20	24	underlying	underlying	JJ
cord-268347-xz6fptol	20	25	medical	medical	JJ
cord-268347-xz6fptol	20	26	comorbidities	comorbiditie	NNS
cord-268347-xz6fptol	20	27	[	[	-LRB-
cord-268347-xz6fptol	20	28	1	1	CD
cord-268347-xz6fptol	20	29	,	,	,
cord-268347-xz6fptol	20	30	2	2	CD
cord-268347-xz6fptol	20	31	]	]	-RRB-
cord-268347-xz6fptol	20	32	.	.	.
cord-268347-xz6fptol	21	1	Nevertheless	nevertheless	RB
cord-268347-xz6fptol	21	2	,	,	,
cord-268347-xz6fptol	21	3	thus	thus	RB
cord-268347-xz6fptol	21	4	far	far	RB
cord-268347-xz6fptol	21	5	,	,	,
cord-268347-xz6fptol	21	6	there	there	EX
cord-268347-xz6fptol	21	7	is	be	VBZ
cord-268347-xz6fptol	21	8	no	no	DT
cord-268347-xz6fptol	21	9	reported	report	VBN
cord-268347-xz6fptol	21	10	association	association	NN
cord-268347-xz6fptol	21	11	between	between	IN
cord-268347-xz6fptol	21	12	the	the	DT
cord-268347-xz6fptol	21	13	presence	presence	NN
cord-268347-xz6fptol	21	14	of	of	IN
cord-268347-xz6fptol	21	15	systemic	systemic	JJ
cord-268347-xz6fptol	21	16	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	21	17	disease	disease	NN
cord-268347-xz6fptol	21	18	(	(	-LRB-
cord-268347-xz6fptol	21	19	e.g.	e.g.	IN
cord-268347-xz6fptol	21	20	rheumatoid	rheumatoid	JJ
cord-268347-xz6fptol	21	21	arthritis	arthritis	NN
cord-268347-xz6fptol	21	22	,	,	,
cord-268347-xz6fptol	21	23	psoriatic	psoriatic	JJ
cord-268347-xz6fptol	21	24	arthritis	arthritis	NN
cord-268347-xz6fptol	21	25	,	,	,
cord-268347-xz6fptol	21	26	ankylosing	ankylosing	NN
cord-268347-xz6fptol	21	27	spondylitis	spondylitis	NN
cord-268347-xz6fptol	21	28	,	,	,
cord-268347-xz6fptol	21	29	systemic	systemic	JJ
cord-268347-xz6fptol	21	30	lupus	lupus	NN
cord-268347-xz6fptol	21	31	erythematosus	erythematosus	NN
cord-268347-xz6fptol	21	32	,	,	,
cord-268347-xz6fptol	21	33	etc	etc	FW
cord-268347-xz6fptol	21	34	.	.	.
cord-268347-xz6fptol	21	35	)	)	-RRB-
cord-268347-xz6fptol	21	36	and	and	CC
cord-268347-xz6fptol	21	37	increased	increase	VBN
cord-268347-xz6fptol	21	38	risk	risk	NN
cord-268347-xz6fptol	21	39	of	of	IN
cord-268347-xz6fptol	21	40	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	21	41	acquisition	acquisition	NN
cord-268347-xz6fptol	21	42	or	or	CC
cord-268347-xz6fptol	21	43	even	even	RB
cord-268347-xz6fptol	21	44	a	a	DT
cord-268347-xz6fptol	21	45	worse	bad	JJR
cord-268347-xz6fptol	21	46	prognosis	prognosis	NN
cord-268347-xz6fptol	21	47	from	from	IN
cord-268347-xz6fptol	21	48	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	21	49	.	.	.
cord-268347-xz6fptol	22	1	In	in	IN
cord-268347-xz6fptol	22	2	one	one	CD
cord-268347-xz6fptol	22	3	prospective	prospective	JJ
cord-268347-xz6fptol	22	4	case	case	NN
cord-268347-xz6fptol	22	5	series	series	NN
cord-268347-xz6fptol	22	6	of	of	IN
cord-268347-xz6fptol	22	7	86	86	CD
cord-268347-xz6fptol	22	8	patients	patient	NNS
cord-268347-xz6fptol	22	9	in	in	IN
cord-268347-xz6fptol	22	10	New	New	NNP
cord-268347-xz6fptol	22	11	York	York	NNP
cord-268347-xz6fptol	22	12	with	with	IN
cord-268347-xz6fptol	22	13	immune	immune	NN
cord-268347-xz6fptol	22	14	-	-	HYPH
cord-268347-xz6fptol	22	15	mediated	mediate	VBN
cord-268347-xz6fptol	22	16	inflammatory	inflammatory	JJ
cord-268347-xz6fptol	22	17	diseases	disease	NNS
cord-268347-xz6fptol	22	18	(	(	-LRB-
cord-268347-xz6fptol	22	19	24	24	CD
cord-268347-xz6fptol	22	20	%	%	NN
cord-268347-xz6fptol	22	21	with	with	IN
cord-268347-xz6fptol	22	22	psoriatic	psoriatic	JJ
cord-268347-xz6fptol	22	23	arthritis	arthritis	NN
cord-268347-xz6fptol	22	24	,	,	,
cord-268347-xz6fptol	22	25	23	23	CD
cord-268347-xz6fptol	22	26	%	%	NN
cord-268347-xz6fptol	22	27	with	with	IN
cord-268347-xz6fptol	22	28	rheumatoid	rheumatoid	NN
cord-268347-xz6fptol	22	29	arthritis	arthritis	NN
cord-268347-xz6fptol	22	30	and	and	CC
cord-268347-xz6fptol	22	31	10	10	CD
cord-268347-xz6fptol	22	32	%	%	NN
cord-268347-xz6fptol	22	33	with	with	IN
cord-268347-xz6fptol	22	34	ankylosing	ankylosing	NNP
cord-268347-xz6fptol	22	35	spondylitis	spondylitis	NNP
cord-268347-xz6fptol	22	36	)	)	-RRB-
cord-268347-xz6fptol	22	37	diagnosed	diagnose	VBN
cord-268347-xz6fptol	22	38	with	with	IN
cord-268347-xz6fptol	22	39	or	or	CC
cord-268347-xz6fptol	22	40	presumed	presume	VBN
cord-268347-xz6fptol	22	41	to	to	TO
cord-268347-xz6fptol	22	42	have	have	VB
cord-268347-xz6fptol	22	43	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	22	44	,	,	,
cord-268347-xz6fptol	22	45	the	the	DT
cord-268347-xz6fptol	22	46	proportion	proportion	NN
cord-268347-xz6fptol	22	47	of	of	IN
cord-268347-xz6fptol	22	48	patients	patient	NNS
cord-268347-xz6fptol	22	49	requiring	require	VBG
cord-268347-xz6fptol	22	50	hospitalization	hospitalization	NN
cord-268347-xz6fptol	22	51	(	(	-LRB-
cord-268347-xz6fptol	22	52	14	14	CD
cord-268347-xz6fptol	22	53	of	of	IN
cord-268347-xz6fptol	22	54	86	86	CD
cord-268347-xz6fptol	22	55	patients	patient	NNS
cord-268347-xz6fptol	22	56	;	;	:
cord-268347-xz6fptol	22	57	16	16	CD
cord-268347-xz6fptol	22	58	%	%	NN
cord-268347-xz6fptol	22	59	)	)	-RRB-
cord-268347-xz6fptol	22	60	was	be	VBD
cord-268347-xz6fptol	22	61	similar	similar	JJ
cord-268347-xz6fptol	22	62	to	to	IN
cord-268347-xz6fptol	22	63	the	the	DT
cord-268347-xz6fptol	22	64	general	general	JJ
cord-268347-xz6fptol	22	65	population	population	NN
cord-268347-xz6fptol	22	66	in	in	IN
cord-268347-xz6fptol	22	67	New	New	NNP
cord-268347-xz6fptol	22	68	York	York	NNP
cord-268347-xz6fptol	22	69	(	(	-LRB-
cord-268347-xz6fptol	22	70	26	26	CD
cord-268347-xz6fptol	22	71	%	%	NN
cord-268347-xz6fptol	22	72	at	at	IN
cord-268347-xz6fptol	22	73	the	the	DT
cord-268347-xz6fptol	22	74	time	time	NN
cord-268347-xz6fptol	22	75	of	of	IN
cord-268347-xz6fptol	22	76	reporting	reporting	NN
cord-268347-xz6fptol	22	77	)	)	-RRB-
cord-268347-xz6fptol	22	78	[	[	-LRB-
cord-268347-xz6fptol	22	79	3	3	CD
cord-268347-xz6fptol	22	80	]	]	-RRB-
cord-268347-xz6fptol	22	81	.	.	.
cord-268347-xz6fptol	23	1	In	in	IN
cord-268347-xz6fptol	23	2	another	another	DT
cord-268347-xz6fptol	23	3	case	case	NN
cord-268347-xz6fptol	23	4	series	series	NN
cord-268347-xz6fptol	23	5	from	from	IN
cord-268347-xz6fptol	23	6	the	the	DT
cord-268347-xz6fptol	23	7	Lombardy	Lombardy	NNP
cord-268347-xz6fptol	23	8	region	region	NN
cord-268347-xz6fptol	23	9	of	of	IN
cord-268347-xz6fptol	23	10	Italy	Italy	NNP
cord-268347-xz6fptol	23	11	,	,	,
cord-268347-xz6fptol	23	12	among	among	IN
cord-268347-xz6fptol	23	13	320	320	CD
cord-268347-xz6fptol	23	14	patients	patient	NNS
cord-268347-xz6fptol	23	15	with	with	IN
cord-268347-xz6fptol	23	16	chronic	chronic	JJ
cord-268347-xz6fptol	23	17	arthritis	arthritis	NN
cord-268347-xz6fptol	23	18	receiving	receive	VBG
cord-268347-xz6fptol	23	19	a	a	DT
cord-268347-xz6fptol	23	20	disease	disease	NN
cord-268347-xz6fptol	23	21	-	-	HYPH
cord-268347-xz6fptol	23	22	modifying	modify	VBG
cord-268347-xz6fptol	23	23	antirheumatic	antirheumatic	JJ
cord-268347-xz6fptol	23	24	drug	drug	NN
cord-268347-xz6fptol	23	25	(	(	-LRB-
cord-268347-xz6fptol	23	26	DMARD	DMARD	NNP
cord-268347-xz6fptol	23	27	)	)	-RRB-
cord-268347-xz6fptol	23	28	,	,	,
cord-268347-xz6fptol	23	29	eight	eight	CD
cord-268347-xz6fptol	23	30	patients	patient	NNS
cord-268347-xz6fptol	23	31	were	be	VBD
cord-268347-xz6fptol	23	32	diagnosed	diagnose	VBN
cord-268347-xz6fptol	23	33	with	with	IN
cord-268347-xz6fptol	23	34	or	or	CC
cord-268347-xz6fptol	23	35	strongly	strongly	RB
cord-268347-xz6fptol	23	36	suspected	suspect	VBN
cord-268347-xz6fptol	23	37	of	of	IN
cord-268347-xz6fptol	23	38	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	23	39	,	,	,
cord-268347-xz6fptol	23	40	but	but	CC
cord-268347-xz6fptol	23	41	only	only	RB
cord-268347-xz6fptol	23	42	one	one	CD
cord-268347-xz6fptol	23	43	patient	patient	NN
cord-268347-xz6fptol	23	44	required	require	VBN
cord-268347-xz6fptol	23	45	hospital	hospital	NN
cord-268347-xz6fptol	23	46	admission	admission	NN
cord-268347-xz6fptol	23	47	[	[	-LRB-
cord-268347-xz6fptol	23	48	4	4	CD
cord-268347-xz6fptol	23	49	]	]	-RRB-
cord-268347-xz6fptol	23	50	.	.	.
cord-268347-xz6fptol	24	1	A	a	DT
cord-268347-xz6fptol	24	2	comparison	comparison	NN
cord-268347-xz6fptol	24	3	with	with	IN
cord-268347-xz6fptol	24	4	>	>	XX
cord-268347-xz6fptol	24	5	33,000	33,000	CD
cord-268347-xz6fptol	24	6	cases	case	NNS
cord-268347-xz6fptol	24	7	of	of	IN
cord-268347-xz6fptol	24	8	COVID-19	covid-19	CD
cord-268347-xz6fptol	24	9	in	in	IN
cord-268347-xz6fptol	24	10	this	this	DT
cord-268347-xz6fptol	24	11	region	region	NN
cord-268347-xz6fptol	24	12	including	include	VBG
cord-268347-xz6fptol	24	13	>	>	XX
cord-268347-xz6fptol	24	14	1250	1250	CD
cord-268347-xz6fptol	24	15	patients	patient	NNS
cord-268347-xz6fptol	24	16	requiring	require	VBG
cord-268347-xz6fptol	24	17	admission	admission	NN
cord-268347-xz6fptol	24	18	to	to	IN
cord-268347-xz6fptol	24	19	intensive	intensive	JJ
cord-268347-xz6fptol	24	20	care	care	NN
cord-268347-xz6fptol	24	21	units	unit	NNS
cord-268347-xz6fptol	24	22	(	(	-LRB-
cord-268347-xz6fptol	24	23	ICUs	ICUs	NNP
cord-268347-xz6fptol	24	24	)	)	-RRB-
cord-268347-xz6fptol	24	25	during	during	IN
cord-268347-xz6fptol	24	26	this	this	DT
cord-268347-xz6fptol	24	27	period	period	NN
cord-268347-xz6fptol	24	28	suggests	suggest	VBZ
cord-268347-xz6fptol	24	29	the	the	DT
cord-268347-xz6fptol	24	30	risk	risk	NN
cord-268347-xz6fptol	24	31	of	of	IN
cord-268347-xz6fptol	24	32	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	24	33	acquisition	acquisition	NN
cord-268347-xz6fptol	24	34	did	do	VBD
cord-268347-xz6fptol	24	35	not	not	RB
cord-268347-xz6fptol	24	36	increase	increase	VB
cord-268347-xz6fptol	24	37	in	in	IN
cord-268347-xz6fptol	24	38	patients	patient	NNS
cord-268347-xz6fptol	24	39	with	with	IN
cord-268347-xz6fptol	24	40	chronic	chronic	JJ
cord-268347-xz6fptol	24	41	arthritis	arthritis	NN
cord-268347-xz6fptol	24	42	.	.	.
cord-268347-xz6fptol	25	1	Similar	similar	JJ
cord-268347-xz6fptol	25	2	findings	finding	NNS
cord-268347-xz6fptol	25	3	were	be	VBD
cord-268347-xz6fptol	25	4	described	describe	VBN
cord-268347-xz6fptol	25	5	among	among	IN
cord-268347-xz6fptol	25	6	859	859	CD
cord-268347-xz6fptol	25	7	patients	patient	NNS
cord-268347-xz6fptol	25	8	surveyed	survey	VBN
cord-268347-xz6fptol	25	9	by	by	IN
cord-268347-xz6fptol	25	10	telephone	telephone	NN
cord-268347-xz6fptol	25	11	who	who	WP
cord-268347-xz6fptol	25	12	were	be	VBD
cord-268347-xz6fptol	25	13	receiving	receive	VBG
cord-268347-xz6fptol	25	14	DMARDs	dmard	NNS
cord-268347-xz6fptol	25	15	for	for	IN
cord-268347-xz6fptol	25	16	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	25	17	diseases	disease	NNS
cord-268347-xz6fptol	25	18	and	and	CC
cord-268347-xz6fptol	25	19	sarcoidosis	sarcoidosis	NN
cord-268347-xz6fptol	25	20	in	in	IN
cord-268347-xz6fptol	25	21	Siena	Siena	NNP
cord-268347-xz6fptol	25	22	,	,	,
cord-268347-xz6fptol	25	23	Italy	Italy	NNP
cord-268347-xz6fptol	25	24	,	,	,
cord-268347-xz6fptol	25	25	where	where	WRB
cord-268347-xz6fptol	25	26	only	only	RB
cord-268347-xz6fptol	25	27	two	two	CD
cord-268347-xz6fptol	25	28	of	of	IN
cord-268347-xz6fptol	25	29	these	these	DT
cord-268347-xz6fptol	25	30	patients	patient	NNS
cord-268347-xz6fptol	25	31	had	have	VBD
cord-268347-xz6fptol	25	32	been	be	VBN
cord-268347-xz6fptol	25	33	diagnosed	diagnose	VBN
cord-268347-xz6fptol	25	34	with	with	IN
cord-268347-xz6fptol	25	35	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	25	36	[	[	-LRB-
cord-268347-xz6fptol	25	37	5	5	CD
cord-268347-xz6fptol	25	38	]	]	-RRB-
cord-268347-xz6fptol	25	39	.	.	.
cord-268347-xz6fptol	26	1	Furthermore	furthermore	RB
cord-268347-xz6fptol	26	2	,	,	,
cord-268347-xz6fptol	26	3	a	a	DT
cord-268347-xz6fptol	26	4	nationwide	nationwide	JJ
cord-268347-xz6fptol	26	5	study	study	NN
cord-268347-xz6fptol	26	6	in	in	IN
cord-268347-xz6fptol	26	7	Russia	Russia	NNP
cord-268347-xz6fptol	26	8	found	find	VBD
cord-268347-xz6fptol	26	9	that	that	IN
cord-268347-xz6fptol	26	10	the	the	DT
cord-268347-xz6fptol	26	11	prevalence	prevalence	NN
cord-268347-xz6fptol	26	12	of	of	IN
cord-268347-xz6fptol	26	13	systemic	systemic	JJ
cord-268347-xz6fptol	26	14	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	26	15	diseases	disease	NNS
cord-268347-xz6fptol	26	16	among	among	IN
cord-268347-xz6fptol	26	17	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	26	18	patients	patient	NNS
cord-268347-xz6fptol	26	19	admitted	admit	VBN
cord-268347-xz6fptol	26	20	to	to	IN
cord-268347-xz6fptol	26	21	ICUs	ICUs	NNP
cord-268347-xz6fptol	26	22	with	with	IN
cord-268347-xz6fptol	26	23	a	a	DT
cord-268347-xz6fptol	26	24	severe	severe	JJ
cord-268347-xz6fptol	26	25	course	course	NN
cord-268347-xz6fptol	26	26	of	of	IN
cord-268347-xz6fptol	26	27	COVID-19	covid-19	NN
cord-268347-xz6fptol	27	1	was	be	VBD
cord-268347-xz6fptol	27	2	low	low	JJ
cord-268347-xz6fptol	27	3	(	(	-LRB-
cord-268347-xz6fptol	27	4	10	10	CD
cord-268347-xz6fptol	27	5	of	of	IN
cord-268347-xz6fptol	27	6	902	902	CD
cord-268347-xz6fptol	27	7	patients	patient	NNS
cord-268347-xz6fptol	27	8	;	;	:
cord-268347-xz6fptol	27	9	1.1	1.1	CD
cord-268347-xz6fptol	27	10	%	%	NN
cord-268347-xz6fptol	27	11	)	)	-RRB-
cord-268347-xz6fptol	27	12	and	and	CC
cord-268347-xz6fptol	27	13	similar	similar	JJ
cord-268347-xz6fptol	27	14	to	to	IN
cord-268347-xz6fptol	27	15	that	that	DT
cord-268347-xz6fptol	27	16	of	of	IN
cord-268347-xz6fptol	27	17	the	the	DT
cord-268347-xz6fptol	27	18	general	general	JJ
cord-268347-xz6fptol	27	19	Russian	russian	JJ
cord-268347-xz6fptol	27	20	population	population	NN
cord-268347-xz6fptol	27	21	[	[	-LRB-
cord-268347-xz6fptol	27	22	6	6	CD
cord-268347-xz6fptol	27	23	]	]	-RRB-
cord-268347-xz6fptol	27	24	.	.	.
cord-268347-xz6fptol	28	1	Similar	similar	JJ
cord-268347-xz6fptol	28	2	to	to	IN
cord-268347-xz6fptol	28	3	their	-PRON-	PRP$
cord-268347-xz6fptol	28	4	adult	adult	NN
cord-268347-xz6fptol	28	5	counterparts	counterpart	NNS
cord-268347-xz6fptol	28	6	,	,	,
cord-268347-xz6fptol	28	7	paediatric	paediatric	JJ
cord-268347-xz6fptol	28	8	patients	patient	NNS
cord-268347-xz6fptol	28	9	with	with	IN
cord-268347-xz6fptol	28	10	systemic	systemic	JJ
cord-268347-xz6fptol	28	11	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	28	12	disease	disease	NN
cord-268347-xz6fptol	28	13	appear	appear	VBP
cord-268347-xz6fptol	28	14	to	to	TO
cord-268347-xz6fptol	28	15	be	be	VB
cord-268347-xz6fptol	28	16	at	at	IN
cord-268347-xz6fptol	28	17	no	no	DT
cord-268347-xz6fptol	28	18	increased	increase	VBN
cord-268347-xz6fptol	28	19	risk	risk	NN
cord-268347-xz6fptol	28	20	for	for	IN
cord-268347-xz6fptol	28	21	the	the	DT
cord-268347-xz6fptol	28	22	acquisition	acquisition	NN
cord-268347-xz6fptol	28	23	of	of	IN
cord-268347-xz6fptol	28	24	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	28	25	[	[	-LRB-
cord-268347-xz6fptol	28	26	7	7	CD
cord-268347-xz6fptol	28	27	,	,	,
cord-268347-xz6fptol	28	28	8	8	CD
cord-268347-xz6fptol	28	29	]	]	-RRB-
cord-268347-xz6fptol	28	30	.	.	.
cord-268347-xz6fptol	29	1	Despite	despite	IN
cord-268347-xz6fptol	29	2	no	no	DT
cord-268347-xz6fptol	29	3	reported	report	VBN
cord-268347-xz6fptol	29	4	direct	direct	JJ
cord-268347-xz6fptol	29	5	association	association	NN
cord-268347-xz6fptol	29	6	,	,	,
cord-268347-xz6fptol	29	7	it	-PRON-	PRP
cord-268347-xz6fptol	29	8	is	be	VBZ
cord-268347-xz6fptol	29	9	noteworthy	noteworthy	JJ
cord-268347-xz6fptol	29	10	that	that	IN
cord-268347-xz6fptol	29	11	patients	patient	NNS
cord-268347-xz6fptol	29	12	with	with	IN
cord-268347-xz6fptol	29	13	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	29	14	diseases	disease	NNS
cord-268347-xz6fptol	29	15	are	be	VBP
cord-268347-xz6fptol	29	16	frequently	frequently	RB
cord-268347-xz6fptol	29	17	of	of	IN
cord-268347-xz6fptol	29	18	older	old	JJR
cord-268347-xz6fptol	29	19	age	age	NN
cord-268347-xz6fptol	29	20	and	and	CC
cord-268347-xz6fptol	29	21	have	have	VBP
cord-268347-xz6fptol	29	22	comorbidities	comorbiditie	NNS
cord-268347-xz6fptol	29	23	such	such	JJ
cord-268347-xz6fptol	29	24	as	as	IN
cord-268347-xz6fptol	29	25	chronic	chronic	JJ
cord-268347-xz6fptol	29	26	pulmonary	pulmonary	JJ
cord-268347-xz6fptol	29	27	disorders	disorder	NNS
cord-268347-xz6fptol	29	28	,	,	,
cord-268347-xz6fptol	29	29	chronic	chronic	JJ
cord-268347-xz6fptol	29	30	kidney	kidney	NN
cord-268347-xz6fptol	29	31	disease	disease	NN
cord-268347-xz6fptol	29	32	,	,	,
cord-268347-xz6fptol	29	33	cardiovascular	cardiovascular	JJ
cord-268347-xz6fptol	29	34	disease	disease	NN
cord-268347-xz6fptol	29	35	(	(	-LRB-
cord-268347-xz6fptol	29	36	CVD	CVD	NNP
cord-268347-xz6fptol	29	37	)	)	-RRB-
cord-268347-xz6fptol	29	38	,	,	,
cord-268347-xz6fptol	29	39	hypertension	hypertension	NN
cord-268347-xz6fptol	29	40	,	,	,
cord-268347-xz6fptol	29	41	obesity	obesity	NN
cord-268347-xz6fptol	29	42	and	and	CC
cord-268347-xz6fptol	29	43	diabetes	diabetes	NN
cord-268347-xz6fptol	29	44	mellitus	mellitus	NN
cord-268347-xz6fptol	29	45	.	.	.
cord-268347-xz6fptol	30	1	These	these	DT
cord-268347-xz6fptol	30	2	comorbidities	comorbiditie	NNS
cord-268347-xz6fptol	30	3	,	,	,
cord-268347-xz6fptol	30	4	in	in	IN
cord-268347-xz6fptol	30	5	turn	turn	NN
cord-268347-xz6fptol	30	6	,	,	,
cord-268347-xz6fptol	30	7	are	be	VBP
cord-268347-xz6fptol	30	8	risk	risk	NN
cord-268347-xz6fptol	30	9	factors	factor	NNS
cord-268347-xz6fptol	30	10	for	for	IN
cord-268347-xz6fptol	30	11	a	a	DT
cord-268347-xz6fptol	30	12	severe	severe	JJ
cord-268347-xz6fptol	30	13	course	course	NN
cord-268347-xz6fptol	30	14	of	of	IN
cord-268347-xz6fptol	30	15	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	30	16	[	[	-LRB-
cord-268347-xz6fptol	30	17	9	9	CD
cord-268347-xz6fptol	30	18	]	]	-RRB-
cord-268347-xz6fptol	31	1	[	[	-LRB-
cord-268347-xz6fptol	31	2	10	10	CD
cord-268347-xz6fptol	31	3	]	]	-RRB-
cord-268347-xz6fptol	31	4	[	[	-LRB-
cord-268347-xz6fptol	31	5	11	11	CD
cord-268347-xz6fptol	31	6	]	]	-RRB-
cord-268347-xz6fptol	31	7	[	[	-LRB-
cord-268347-xz6fptol	31	8	12	12	CD
cord-268347-xz6fptol	31	9	]	]	-RRB-
cord-268347-xz6fptol	31	10	[	[	-LRB-
cord-268347-xz6fptol	31	11	13	13	CD
cord-268347-xz6fptol	31	12	]	]	-RRB-
cord-268347-xz6fptol	32	1	[	[	-LRB-
cord-268347-xz6fptol	32	2	14	14	CD
cord-268347-xz6fptol	32	3	]	]	-RRB-
cord-268347-xz6fptol	32	4	[	[	-LRB-
cord-268347-xz6fptol	32	5	15	15	CD
cord-268347-xz6fptol	32	6	]	]	-RRB-
cord-268347-xz6fptol	32	7	.	.	.
cord-268347-xz6fptol	33	1	For	for	IN
cord-268347-xz6fptol	33	2	instance	instance	NN
cord-268347-xz6fptol	33	3	,	,	,
cord-268347-xz6fptol	33	4	a	a	DT
cord-268347-xz6fptol	33	5	meta	meta	NN
cord-268347-xz6fptol	33	6	-	-	HYPH
cord-268347-xz6fptol	33	7	analysis	analysis	NN
cord-268347-xz6fptol	33	8	of	of	IN
cord-268347-xz6fptol	33	9	24	24	CD
cord-268347-xz6fptol	33	10	observational	observational	JJ
cord-268347-xz6fptol	33	11	studies	study	NNS
cord-268347-xz6fptol	33	12	that	that	WDT
cord-268347-xz6fptol	33	13	included	include	VBD
cord-268347-xz6fptol	33	14	111,758	111,758	CD
cord-268347-xz6fptol	33	15	patients	patient	NNS
cord-268347-xz6fptol	33	16	reported	report	VBD
cord-268347-xz6fptol	33	17	a	a	DT
cord-268347-xz6fptol	33	18	59	59	CD
cord-268347-xz6fptol	33	19	%	%	NN
cord-268347-xz6fptol	33	20	higher	high	JJR
cord-268347-xz6fptol	33	21	risk	risk	NN
cord-268347-xz6fptol	33	22	of	of	IN
cord-268347-xz6fptol	33	23	mortality	mortality	NN
cord-268347-xz6fptol	33	24	from	from	IN
cord-268347-xz6fptol	33	25	coronary	coronary	JJ
cord-268347-xz6fptol	33	26	artery	artery	NN
cord-268347-xz6fptol	33	27	disease	disease	NN
cord-268347-xz6fptol	33	28	in	in	IN
cord-268347-xz6fptol	33	29	patients	patient	NNS
cord-268347-xz6fptol	33	30	with	with	IN
cord-268347-xz6fptol	33	31	rheumatoid	rheumatoid	NN
cord-268347-xz6fptol	33	32	arthritis	arthritis	NN
cord-268347-xz6fptol	33	33	relative	relative	JJ
cord-268347-xz6fptol	33	34	to	to	IN
cord-268347-xz6fptol	33	35	the	the	DT
cord-268347-xz6fptol	33	36	general	general	JJ
cord-268347-xz6fptol	33	37	population	population	NN
cord-268347-xz6fptol	33	38	[	[	-LRB-
cord-268347-xz6fptol	33	39	16	16	CD
cord-268347-xz6fptol	33	40	]	]	-RRB-
cord-268347-xz6fptol	33	41	.	.	.
cord-268347-xz6fptol	34	1	In	in	IN
cord-268347-xz6fptol	34	2	addition	addition	NN
cord-268347-xz6fptol	34	3	,	,	,
cord-268347-xz6fptol	34	4	a	a	DT
cord-268347-xz6fptol	34	5	systematic	systematic	JJ
cord-268347-xz6fptol	34	6	review	review	NN
cord-268347-xz6fptol	34	7	of	of	IN
cord-268347-xz6fptol	34	8	28	28	CD
cord-268347-xz6fptol	34	9	studies	study	NNS
cord-268347-xz6fptol	34	10	concluded	conclude	VBD
cord-268347-xz6fptol	34	11	that	that	IN
cord-268347-xz6fptol	34	12	patients	patient	NNS
cord-268347-xz6fptol	34	13	with	with	IN
cord-268347-xz6fptol	34	14	systemic	systemic	JJ
cord-268347-xz6fptol	34	15	lupus	lupus	NN
cord-268347-xz6fptol	34	16	erythematosus	erythematosus	NN
cord-268347-xz6fptol	34	17	had	have	VBD
cord-268347-xz6fptol	34	18	at	at	IN
cord-268347-xz6fptol	34	19	least	least	JJS
cord-268347-xz6fptol	34	20	double	double	PDT
cord-268347-xz6fptol	34	21	the	the	DT
cord-268347-xz6fptol	34	22	risk	risk	NN
cord-268347-xz6fptol	34	23	of	of	IN
cord-268347-xz6fptol	34	24	CVD	CVD	NNP
cord-268347-xz6fptol	34	25	(	(	-LRB-
cord-268347-xz6fptol	34	26	myocardial	myocardial	JJ
cord-268347-xz6fptol	34	27	infarction	infarction	NN
cord-268347-xz6fptol	34	28	,	,	,
cord-268347-xz6fptol	34	29	cerebrovascular	cerebrovascular	JJ
cord-268347-xz6fptol	34	30	disease	disease	NN
cord-268347-xz6fptol	34	31	and	and	CC
cord-268347-xz6fptol	34	32	peripheral	peripheral	JJ
cord-268347-xz6fptol	34	33	vascular	vascular	JJ
cord-268347-xz6fptol	34	34	disease	disease	NN
cord-268347-xz6fptol	34	35	)	)	-RRB-
cord-268347-xz6fptol	34	36	compared	compare	VBN
cord-268347-xz6fptol	34	37	with	with	IN
cord-268347-xz6fptol	34	38	the	the	DT
cord-268347-xz6fptol	34	39	general	general	JJ
cord-268347-xz6fptol	34	40	population	population	NN
cord-268347-xz6fptol	34	41	[	[	-LRB-
cord-268347-xz6fptol	34	42	17	17	CD
cord-268347-xz6fptol	34	43	]	]	-RRB-
cord-268347-xz6fptol	34	44	.	.	.
cord-268347-xz6fptol	35	1	It	-PRON-	PRP
cord-268347-xz6fptol	35	2	is	be	VBZ
cord-268347-xz6fptol	35	3	not	not	RB
cord-268347-xz6fptol	35	4	known	know	VBN
cord-268347-xz6fptol	35	5	definitely	definitely	RB
cord-268347-xz6fptol	35	6	whether	whether	IN
cord-268347-xz6fptol	35	7	there	there	EX
cord-268347-xz6fptol	35	8	is	be	VBZ
cord-268347-xz6fptol	35	9	an	an	DT
cord-268347-xz6fptol	35	10	association	association	NN
cord-268347-xz6fptol	35	11	between	between	IN
cord-268347-xz6fptol	35	12	the	the	DT
cord-268347-xz6fptol	35	13	use	use	NN
cord-268347-xz6fptol	35	14	of	of	IN
cord-268347-xz6fptol	35	15	any	any	DT
cord-268347-xz6fptol	35	16	DMARD	DMARD	NNP
cord-268347-xz6fptol	35	17	,	,	,
cord-268347-xz6fptol	35	18	including	include	VBG
cord-268347-xz6fptol	35	19	biological	biological	JJ
cord-268347-xz6fptol	35	20	and	and	CC
cord-268347-xz6fptol	35	21	non	non	JJ
cord-268347-xz6fptol	35	22	-	-	JJ
cord-268347-xz6fptol	35	23	biological	biological	JJ
cord-268347-xz6fptol	35	24	agents	agent	NNS
cord-268347-xz6fptol	35	25	,	,	,
cord-268347-xz6fptol	35	26	and	and	CC
cord-268347-xz6fptol	35	27	an	an	DT
cord-268347-xz6fptol	35	28	increased	increase	VBN
cord-268347-xz6fptol	35	29	risk	risk	NN
cord-268347-xz6fptol	35	30	of	of	IN
cord-268347-xz6fptol	35	31	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	35	32	acquisition	acquisition	NN
cord-268347-xz6fptol	35	33	or	or	CC
cord-268347-xz6fptol	35	34	adverse	adverse	JJ
cord-268347-xz6fptol	35	35	outcomes	outcome	NNS
cord-268347-xz6fptol	35	36	from	from	IN
cord-268347-xz6fptol	35	37	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	35	38	.	.	.
cord-268347-xz6fptol	36	1	However	however	RB
cord-268347-xz6fptol	36	2	,	,	,
cord-268347-xz6fptol	36	3	pharmacological	pharmacological	JJ
cord-268347-xz6fptol	36	4	agents	agent	NNS
cord-268347-xz6fptol	36	5	used	use	VBD
cord-268347-xz6fptol	36	6	to	to	TO
cord-268347-xz6fptol	36	7	treat	treat	VB
cord-268347-xz6fptol	36	8	systemic	systemic	JJ
cord-268347-xz6fptol	36	9	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	36	10	diseases	disease	NNS
cord-268347-xz6fptol	36	11	have	have	VBP
cord-268347-xz6fptol	36	12	been	be	VBN
cord-268347-xz6fptol	36	13	associated	associate	VBN
cord-268347-xz6fptol	36	14	with	with	IN
cord-268347-xz6fptol	36	15	an	an	DT
cord-268347-xz6fptol	36	16	overall	overall	JJ
cord-268347-xz6fptol	36	17	higher	high	JJR
cord-268347-xz6fptol	36	18	risk	risk	NN
cord-268347-xz6fptol	36	19	of	of	IN
cord-268347-xz6fptol	36	20	infections	infection	NNS
cord-268347-xz6fptol	36	21	in	in	IN
cord-268347-xz6fptol	36	22	both	both	DT
cord-268347-xz6fptol	36	23	adult	adult	NN
cord-268347-xz6fptol	36	24	and	and	CC
cord-268347-xz6fptol	36	25	paediatric	paediatric	JJ
cord-268347-xz6fptol	36	26	populations	population	NNS
cord-268347-xz6fptol	36	27	[	[	-LRB-
cord-268347-xz6fptol	36	28	18	18	CD
cord-268347-xz6fptol	36	29	,	,	,
cord-268347-xz6fptol	36	30	19	19	CD
cord-268347-xz6fptol	36	31	]	]	-RRB-
cord-268347-xz6fptol	36	32	.	.	.
cord-268347-xz6fptol	37	1	Findings	finding	NNS
cord-268347-xz6fptol	37	2	from	from	IN
cord-268347-xz6fptol	37	3	emerging	emerge	VBG
cord-268347-xz6fptol	37	4	observational	observational	JJ
cord-268347-xz6fptol	37	5	studies	study	NNS
cord-268347-xz6fptol	37	6	have	have	VBP
cord-268347-xz6fptol	37	7	been	be	VBN
cord-268347-xz6fptol	37	8	mixed	mix	VBN
cord-268347-xz6fptol	37	9	.	.	.
cord-268347-xz6fptol	38	1	To	to	TO
cord-268347-xz6fptol	38	2	illustrate	illustrate	VB
cord-268347-xz6fptol	38	3	,	,	,
cord-268347-xz6fptol	38	4	the	the	DT
cord-268347-xz6fptol	38	5	aforementioned	aforementioned	JJ
cord-268347-xz6fptol	38	6	prospective	prospective	JJ
cord-268347-xz6fptol	38	7	case	case	NN
cord-268347-xz6fptol	38	8	series	series	NN
cord-268347-xz6fptol	38	9	[	[	-LRB-
cord-268347-xz6fptol	38	10	3	3	CD
cord-268347-xz6fptol	38	11	]	]	-RRB-
cord-268347-xz6fptol	38	12	that	that	WDT
cord-268347-xz6fptol	38	13	included	include	VBD
cord-268347-xz6fptol	38	14	86	86	CD
cord-268347-xz6fptol	38	15	patients	patient	NNS
cord-268347-xz6fptol	38	16	from	from	IN
cord-268347-xz6fptol	38	17	New	New	NNP
cord-268347-xz6fptol	38	18	York	York	NNP
cord-268347-xz6fptol	38	19	with	with	IN
cord-268347-xz6fptol	38	20	confirmed	confirmed	JJ
cord-268347-xz6fptol	38	21	or	or	CC
cord-268347-xz6fptol	38	22	presumptive	presumptive	JJ
cord-268347-xz6fptol	38	23	COVID-19	covid-19	NN
cord-268347-xz6fptol	38	24	with	with	IN
cord-268347-xz6fptol	38	25	concurrent	concurrent	JJ
cord-268347-xz6fptol	38	26	immunemediated	immunemediated	JJ
cord-268347-xz6fptol	38	27	inflammatory	inflammatory	JJ
cord-268347-xz6fptol	38	28	disease	disease	NN
cord-268347-xz6fptol	38	29	reported	report	VBD
cord-268347-xz6fptol	38	30	no	no	DT
cord-268347-xz6fptol	38	31	increased	increase	VBN
cord-268347-xz6fptol	38	32	odds	odd	NNS
cord-268347-xz6fptol	38	33	of	of	IN
cord-268347-xz6fptol	38	34	COVID-19	covid-19	JJ
cord-268347-xz6fptol	38	35	hospitalization	hospitalization	NN
cord-268347-xz6fptol	38	36	among	among	IN
cord-268347-xz6fptol	38	37	those	those	DT
cord-268347-xz6fptol	38	38	who	who	WP
cord-268347-xz6fptol	38	39	were	be	VBD
cord-268347-xz6fptol	38	40	receiving	receive	VBG
cord-268347-xz6fptol	38	41	biological	biological	JJ
cord-268347-xz6fptol	38	42	agents	agent	NNS
cord-268347-xz6fptol	38	43	or	or	CC
cord-268347-xz6fptol	38	44	Janus	Janus	NNP
cord-268347-xz6fptol	38	45	kinase	kinase	NN
cord-268347-xz6fptol	38	46	(	(	-LRB-
cord-268347-xz6fptol	38	47	JAK	JAK	NNP
cord-268347-xz6fptol	38	48	)	)	-RRB-
cord-268347-xz6fptol	38	49	inhibitors	inhibitor	NNS
cord-268347-xz6fptol	38	50	at	at	IN
cord-268347-xz6fptol	38	51	baseline	baseline	NN
cord-268347-xz6fptol	38	52	[	[	-LRB-
cord-268347-xz6fptol	38	53	adjusted	adjust	VBN
cord-268347-xz6fptol	38	54	odds	odd	NNS
cord-268347-xz6fptol	38	55	ratio	ratio	NN
cord-268347-xz6fptol	38	56	(	(	-LRB-
cord-268347-xz6fptol	38	57	OR	OR	NNP
cord-268347-xz6fptol	38	58	)	)	-RRB-
cord-268347-xz6fptol	38	59	0.85	0.85	CD
cord-268347-xz6fptol	38	60	;	;	:
cord-268347-xz6fptol	38	61	95	95	CD
cord-268347-xz6fptol	38	62	%	%	NN
cord-268347-xz6fptol	38	63	CI	CI	NNP
cord-268347-xz6fptol	38	64	0.71	0.71	CD
cord-268347-xz6fptol	38	65	-	-	HYPH
cord-268347-xz6fptol	38	66	1.02	1.02	CD
cord-268347-xz6fptol	38	67	]	]	-RRB-
cord-268347-xz6fptol	38	68	.	.	.
cord-268347-xz6fptol	39	1	In	in	IN
cord-268347-xz6fptol	39	2	contrast	contrast	NN
cord-268347-xz6fptol	39	3	,	,	,
cord-268347-xz6fptol	39	4	patients	patient	NNS
cord-268347-xz6fptol	39	5	receiving	receive	VBG
cord-268347-xz6fptol	39	6	methotrexate	methotrexate	NNP
cord-268347-xz6fptol	39	7	at	at	IN
cord-268347-xz6fptol	39	8	baseline	baseline	NN
cord-268347-xz6fptol	39	9	were	be	VBD
cord-268347-xz6fptol	39	10	at	at	IN
cord-268347-xz6fptol	39	11	significantly	significantly	RB
cord-268347-xz6fptol	39	12	increased	increase	VBN
cord-268347-xz6fptol	39	13	odds	odd	NNS
cord-268347-xz6fptol	39	14	of	of	IN
cord-268347-xz6fptol	39	15	being	be	VBG
cord-268347-xz6fptol	39	16	hospitalized	hospitalize	VBN
cord-268347-xz6fptol	39	17	for	for	IN
cord-268347-xz6fptol	39	18	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	39	19	(	(	-LRB-
cord-268347-xz6fptol	39	20	adjusted	adjust	VBN
cord-268347-xz6fptol	39	21	OR	or	CC
cord-268347-xz6fptol	39	22	1.29	1.29	CD
cord-268347-xz6fptol	39	23	;	;	:
cord-268347-xz6fptol	39	24	95	95	CD
cord-268347-xz6fptol	39	25	%	%	NN
cord-268347-xz6fptol	39	26	CI	CI	NNP
cord-268347-xz6fptol	39	27	1.04	1.04	CD
cord-268347-xz6fptol	39	28	-	-	SYM
cord-268347-xz6fptol	39	29	1.58	1.58	CD
cord-268347-xz6fptol	39	30	)	)	-RRB-
cord-268347-xz6fptol	39	31	.	.	.
cord-268347-xz6fptol	40	1	On	on	IN
cord-268347-xz6fptol	40	2	the	the	DT
cord-268347-xz6fptol	40	3	other	other	JJ
cord-268347-xz6fptol	40	4	hand	hand	NN
cord-268347-xz6fptol	40	5	,	,	,
cord-268347-xz6fptol	40	6	a	a	DT
cord-268347-xz6fptol	40	7	single	single	JJ
cord-268347-xz6fptol	40	8	-	-	HYPH
cord-268347-xz6fptol	40	9	centre	centre	NN
cord-268347-xz6fptol	40	10	case	case	NN
cord-268347-xz6fptol	40	11	-	-	HYPH
cord-268347-xz6fptol	40	12	control	control	NN
cord-268347-xz6fptol	40	13	study	study	NN
cord-268347-xz6fptol	40	14	[	[	-LRB-
cord-268347-xz6fptol	40	15	20	20	CD
cord-268347-xz6fptol	40	16	]	]	-RRB-
cord-268347-xz6fptol	40	17	in	in	IN
cord-268347-xz6fptol	40	18	the	the	DT
cord-268347-xz6fptol	40	19	Lombardy	Lombardy	NNP
cord-268347-xz6fptol	40	20	region	region	NN
cord-268347-xz6fptol	40	21	of	of	IN
cord-268347-xz6fptol	40	22	Italy	Italy	NNP
cord-268347-xz6fptol	40	23	that	that	WDT
cord-268347-xz6fptol	40	24	included	include	VBD
cord-268347-xz6fptol	40	25	1193	1193	CD
cord-268347-xz6fptol	40	26	patients	patient	NNS
cord-268347-xz6fptol	40	27	with	with	IN
cord-268347-xz6fptol	40	28	psoriasis	psoriasis	NN
cord-268347-xz6fptol	40	29	receiving	receive	VBG
cord-268347-xz6fptol	40	30	either	either	CC
cord-268347-xz6fptol	40	31	biological	biological	JJ
cord-268347-xz6fptol	40	32	agents	agent	NNS
cord-268347-xz6fptol	40	33	or	or	CC
cord-268347-xz6fptol	40	34	conventional	conventional	JJ
cord-268347-xz6fptol	40	35	small	small	JJ
cord-268347-xz6fptol	40	36	-	-	HYPH
cord-268347-xz6fptol	40	37	molecule	molecule	NN
cord-268347-xz6fptol	40	38	drugs	drug	NNS
cord-268347-xz6fptol	40	39	has	have	VBZ
cord-268347-xz6fptol	40	40	reported	report	VBN
cord-268347-xz6fptol	40	41	otherwise	otherwise	RB
cord-268347-xz6fptol	40	42	.	.	.
cord-268347-xz6fptol	41	1	Patients	patient	NNS
cord-268347-xz6fptol	41	2	treated	treat	VBN
cord-268347-xz6fptol	41	3	with	with	IN
cord-268347-xz6fptol	41	4	biological	biological	JJ
cord-268347-xz6fptol	41	5	agents	agent	NNS
cord-268347-xz6fptol	41	6	had	have	VBD
cord-268347-xz6fptol	41	7	significantly	significantly	RB
cord-268347-xz6fptol	41	8	higher	high	JJR
cord-268347-xz6fptol	41	9	odds	odd	NNS
cord-268347-xz6fptol	41	10	of	of	IN
cord-268347-xz6fptol	41	11	developing	develop	VBG
cord-268347-xz6fptol	41	12	symptomatic	symptomatic	JJ
cord-268347-xz6fptol	41	13	COVID-19	covid-19	CD
cord-268347-xz6fptol	41	14	infection	infection	NN
cord-268347-xz6fptol	41	15	(	(	-LRB-
cord-268347-xz6fptol	41	16	OR	or	CC
cord-268347-xz6fptol	41	17	3.43	3.43	CD
cord-268347-xz6fptol	41	18	;	;	:
cord-268347-xz6fptol	41	19	95	95	CD
cord-268347-xz6fptol	41	20	%	%	NN
cord-268347-xz6fptol	41	21	CI	CI	NNP
cord-268347-xz6fptol	41	22	2.25	2.25	CD
cord-268347-xz6fptol	41	23	-	-	HYPH
cord-268347-xz6fptol	41	24	5.73	5.73	CD
cord-268347-xz6fptol	41	25	)	)	-RRB-
cord-268347-xz6fptol	41	26	,	,	,
cord-268347-xz6fptol	41	27	being	be	VBG
cord-268347-xz6fptol	41	28	self	self	NN
cord-268347-xz6fptol	41	29	-	-	HYPH
cord-268347-xz6fptol	41	30	quarantined	quarantine	VBN
cord-268347-xz6fptol	41	31	at	at	IN
cord-268347-xz6fptol	41	32	home	home	NN
cord-268347-xz6fptol	41	33	(	(	-LRB-
cord-268347-xz6fptol	41	34	OR	or	CC
cord-268347-xz6fptol	41	35	9.05	9.05	CD
cord-268347-xz6fptol	41	36	;	;	.
cord-268347-xz6fptol	42	1	95	95	CD
cord-268347-xz6fptol	42	2	%	%	NN
cord-268347-xz6fptol	42	3	CI	CI	NNP
cord-268347-xz6fptol	42	4	5.61	5.61	CD
cord-268347-xz6fptol	42	5	-	-	HYPH
cord-268347-xz6fptol	42	6	14.61	14.61	CD
cord-268347-xz6fptol	42	7	)	)	-RRB-
cord-268347-xz6fptol	42	8	and	and	CC
cord-268347-xz6fptol	42	9	being	be	VBG
cord-268347-xz6fptol	42	10	hospitalized	hospitalize	VBN
cord-268347-xz6fptol	42	11	for	for	IN
cord-268347-xz6fptol	42	12	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	42	13	(	(	-LRB-
cord-268347-xz6fptol	42	14	OR	OR	NNP
cord-268347-xz6fptol	42	15	3.59	3.59	CD
cord-268347-xz6fptol	42	16	;	;	:
cord-268347-xz6fptol	42	17	95	95	CD
cord-268347-xz6fptol	42	18	%	%	NN
cord-268347-xz6fptol	42	19	CI	CI	NNP
cord-268347-xz6fptol	42	20	1.49	1.49	CD
cord-268347-xz6fptol	42	21	-	-	HYPH
cord-268347-xz6fptol	42	22	8.63	8.63	CD
cord-268347-xz6fptol	42	23	)	)	-RRB-
cord-268347-xz6fptol	42	24	than	than	IN
cord-268347-xz6fptol	42	25	the	the	DT
cord-268347-xz6fptol	42	26	general	general	JJ
cord-268347-xz6fptol	42	27	population	population	NN
cord-268347-xz6fptol	42	28	in	in	IN
cord-268347-xz6fptol	42	29	the	the	DT
cord-268347-xz6fptol	42	30	region	region	NN
cord-268347-xz6fptol	42	31	.	.	.
cord-268347-xz6fptol	43	1	The	the	DT
cord-268347-xz6fptol	43	2	odds	odd	NNS
cord-268347-xz6fptol	43	3	of	of	IN
cord-268347-xz6fptol	43	4	admission	admission	NN
cord-268347-xz6fptol	43	5	to	to	IN
cord-268347-xz6fptol	43	6	an	an	DT
cord-268347-xz6fptol	43	7	ICU	ICU	NNP
cord-268347-xz6fptol	43	8	or	or	CC
cord-268347-xz6fptol	43	9	of	of	IN
cord-268347-xz6fptol	43	10	death	death	NN
cord-268347-xz6fptol	43	11	did	do	VBD
cord-268347-xz6fptol	43	12	not	not	RB
cord-268347-xz6fptol	43	13	differ	differ	VB
cord-268347-xz6fptol	43	14	,	,	,
cord-268347-xz6fptol	43	15	although	although	IN
cord-268347-xz6fptol	43	16	there	there	EX
cord-268347-xz6fptol	43	17	had	have	VBD
cord-268347-xz6fptol	43	18	been	be	VBN
cord-268347-xz6fptol	43	19	insufficient	insufficient	JJ
cord-268347-xz6fptol	43	20	number	number	NN
cord-268347-xz6fptol	43	21	of	of	IN
cord-268347-xz6fptol	43	22	patients	patient	NNS
cord-268347-xz6fptol	43	23	in	in	IN
cord-268347-xz6fptol	43	24	the	the	DT
cord-268347-xz6fptol	43	25	study	study	NN
cord-268347-xz6fptol	43	26	to	to	TO
cord-268347-xz6fptol	43	27	provide	provide	VB
cord-268347-xz6fptol	43	28	adequate	adequate	JJ
cord-268347-xz6fptol	43	29	statistical	statistical	JJ
cord-268347-xz6fptol	43	30	power	power	NN
cord-268347-xz6fptol	43	31	[	[	-LRB-
cord-268347-xz6fptol	43	32	20	20	CD
cord-268347-xz6fptol	43	33	]	]	-RRB-
cord-268347-xz6fptol	43	34	.	.	.
cord-268347-xz6fptol	44	1	In	in	IN
cord-268347-xz6fptol	44	2	a	a	DT
cord-268347-xz6fptol	44	3	multinational	multinational	JJ
cord-268347-xz6fptol	44	4	case	case	NN
cord-268347-xz6fptol	44	5	series	series	NN
cord-268347-xz6fptol	44	6	of	of	IN
cord-268347-xz6fptol	44	7	600	600	CD
cord-268347-xz6fptol	44	8	patients	patient	NNS
cord-268347-xz6fptol	44	9	with	with	IN
cord-268347-xz6fptol	44	10	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	44	11	diseases	disease	NNS
cord-268347-xz6fptol	44	12	and	and	CC
cord-268347-xz6fptol	44	13	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	44	14	included	include	VBN
cord-268347-xz6fptol	44	15	in	in	IN
cord-268347-xz6fptol	44	16	the	the	DT
cord-268347-xz6fptol	44	17	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	44	18	Global	Global	NNP
cord-268347-xz6fptol	44	19	Rheumatology	Rheumatology	NNP
cord-268347-xz6fptol	44	20	Alliance	Alliance	NNP
cord-268347-xz6fptol	44	21	physician	physician	NN
cord-268347-xz6fptol	44	22	-	-	HYPH
cord-268347-xz6fptol	44	23	reported	report	VBN
cord-268347-xz6fptol	44	24	registry	registry	NN
cord-268347-xz6fptol	44	25	,	,	,
cord-268347-xz6fptol	44	26	the	the	DT
cord-268347-xz6fptol	44	27	use	use	NN
cord-268347-xz6fptol	44	28	of	of	IN
cord-268347-xz6fptol	44	29	a	a	DT
cord-268347-xz6fptol	44	30	tumour	tumour	NN
cord-268347-xz6fptol	44	31	necrosis	necrosis	NN
cord-268347-xz6fptol	44	32	factor	factor	NN
cord-268347-xz6fptol	44	33	inhibitor	inhibitor	NN
cord-268347-xz6fptol	44	34	was	be	VBD
cord-268347-xz6fptol	44	35	associated	associate	VBN
cord-268347-xz6fptol	44	36	with	with	IN
cord-268347-xz6fptol	44	37	lower	low	JJR
cord-268347-xz6fptol	44	38	odds	odd	NNS
cord-268347-xz6fptol	44	39	of	of	IN
cord-268347-xz6fptol	44	40	hospitalization	hospitalization	NN
cord-268347-xz6fptol	44	41	(	(	-LRB-
cord-268347-xz6fptol	44	42	OR	or	CC
cord-268347-xz6fptol	44	43	0.40	0.40	CD
cord-268347-xz6fptol	44	44	;	;	:
cord-268347-xz6fptol	44	45	95	95	CD
cord-268347-xz6fptol	44	46	%	%	NN
cord-268347-xz6fptol	44	47	CI	CI	NNP
cord-268347-xz6fptol	44	48	0.19	0.19	CD
cord-268347-xz6fptol	44	49	-	-	HYPH
cord-268347-xz6fptol	44	50	0.81	0.81	CD
cord-268347-xz6fptol	44	51	)	)	-RRB-
cord-268347-xz6fptol	44	52	[	[	-LRB-
cord-268347-xz6fptol	44	53	21	21	CD
cord-268347-xz6fptol	44	54	]	]	-RRB-
cord-268347-xz6fptol	44	55	.	.	.
cord-268347-xz6fptol	45	1	There	there	EX
cord-268347-xz6fptol	45	2	was	be	VBD
cord-268347-xz6fptol	45	3	no	no	DT
cord-268347-xz6fptol	45	4	significant	significant	JJ
cord-268347-xz6fptol	45	5	association	association	NN
cord-268347-xz6fptol	45	6	between	between	IN
cord-268347-xz6fptol	45	7	the	the	DT
cord-268347-xz6fptol	45	8	use	use	NN
cord-268347-xz6fptol	45	9	of	of	IN
cord-268347-xz6fptol	45	10	conventional	conventional	JJ
cord-268347-xz6fptol	45	11	DMARDs	dmard	NNS
cord-268347-xz6fptol	45	12	,	,	,
cord-268347-xz6fptol	45	13	either	either	CC
cord-268347-xz6fptol	45	14	alone	alone	RB
cord-268347-xz6fptol	45	15	or	or	CC
cord-268347-xz6fptol	45	16	in	in	IN
cord-268347-xz6fptol	45	17	combination	combination	NN
cord-268347-xz6fptol	45	18	with	with	IN
cord-268347-xz6fptol	45	19	biologicals	biological	NNS
cord-268347-xz6fptol	45	20	/	/	SYM
cord-268347-xz6fptol	45	21	JAK	JAK	NNP
cord-268347-xz6fptol	45	22	inhibitors	inhibitor	NNS
cord-268347-xz6fptol	45	23	,	,	,
cord-268347-xz6fptol	45	24	and	and	CC
cord-268347-xz6fptol	45	25	an	an	DT
cord-268347-xz6fptol	45	26	increased	increase	VBN
cord-268347-xz6fptol	45	27	risk	risk	NN
cord-268347-xz6fptol	45	28	of	of	IN
cord-268347-xz6fptol	45	29	hospitalization	hospitalization	NN
cord-268347-xz6fptol	45	30	for	for	IN
cord-268347-xz6fptol	45	31	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	45	32	[	[	-LRB-
cord-268347-xz6fptol	45	33	21	21	CD
cord-268347-xz6fptol	45	34	]	]	-RRB-
cord-268347-xz6fptol	45	35	.	.	.
cord-268347-xz6fptol	46	1	Based	base	VBN
cord-268347-xz6fptol	46	2	on	on	IN
cord-268347-xz6fptol	46	3	currently	currently	RB
cord-268347-xz6fptol	46	4	available	available	JJ
cord-268347-xz6fptol	46	5	evidence	evidence	NN
cord-268347-xz6fptol	46	6	,	,	,
cord-268347-xz6fptol	46	7	we	-PRON-	PRP
cord-268347-xz6fptol	46	8	feel	feel	VBP
cord-268347-xz6fptol	46	9	that	that	IN
cord-268347-xz6fptol	46	10	pharmacological	pharmacological	JJ
cord-268347-xz6fptol	46	11	management	management	NN
cord-268347-xz6fptol	46	12	for	for	IN
cord-268347-xz6fptol	46	13	patients	patient	NNS
cord-268347-xz6fptol	46	14	with	with	IN
cord-268347-xz6fptol	46	15	newly	newly	RB
cord-268347-xz6fptol	46	16	diagnosed	diagnose	VBN
cord-268347-xz6fptol	46	17	,	,	,
cord-268347-xz6fptol	46	18	stable	stable	JJ
cord-268347-xz6fptol	46	19	,	,	,
cord-268347-xz6fptol	46	20	or	or	CC
cord-268347-xz6fptol	46	21	active	active	JJ
cord-268347-xz6fptol	46	22	systemic	systemic	JJ
cord-268347-xz6fptol	46	23	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	46	24	disease	disease	NN
cord-268347-xz6fptol	46	25	without	without	IN
cord-268347-xz6fptol	46	26	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	46	27	should	should	MD
cord-268347-xz6fptol	46	28	follow	follow	VB
cord-268347-xz6fptol	46	29	usual	usual	JJ
cord-268347-xz6fptol	46	30	treatment	treatment	NN
cord-268347-xz6fptol	46	31	approaches	approach	NNS
cord-268347-xz6fptol	46	32	.	.	.
cord-268347-xz6fptol	47	1	There	there	EX
cord-268347-xz6fptol	47	2	are	be	VBP
cord-268347-xz6fptol	47	3	proven	prove	VBN
cord-268347-xz6fptol	47	4	benefits	benefit	NNS
cord-268347-xz6fptol	47	5	for	for	IN
cord-268347-xz6fptol	47	6	initiation	initiation	NN
cord-268347-xz6fptol	47	7	or	or	CC
cord-268347-xz6fptol	47	8	continuation	continuation	NN
cord-268347-xz6fptol	47	9	of	of	IN
cord-268347-xz6fptol	47	10	any	any	DT
cord-268347-xz6fptol	47	11	pharmacological	pharmacological	JJ
cord-268347-xz6fptol	47	12	agents	agent	NNS
cord-268347-xz6fptol	47	13	for	for	IN
cord-268347-xz6fptol	47	14	the	the	DT
cord-268347-xz6fptol	47	15	management	management	NN
cord-268347-xz6fptol	47	16	of	of	IN
cord-268347-xz6fptol	47	17	systemic	systemic	JJ
cord-268347-xz6fptol	47	18	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	47	19	diseases	disease	NNS
cord-268347-xz6fptol	47	20	,	,	,
cord-268347-xz6fptol	47	21	including	include	VBG
cord-268347-xz6fptol	47	22	treatment	treatment	NN
cord-268347-xz6fptol	47	23	with	with	IN
cord-268347-xz6fptol	47	24	conventional	conventional	JJ
cord-268347-xz6fptol	47	25	DMARDs	dmard	NNS
cord-268347-xz6fptol	47	26	and	and	CC
cord-268347-xz6fptol	47	27	other	other	JJ
cord-268347-xz6fptol	47	28	immunosuppressive	immunosuppressive	JJ
cord-268347-xz6fptol	47	29	agents	agent	NNS
cord-268347-xz6fptol	47	30	(	(	-LRB-
cord-268347-xz6fptol	47	31	e.g.	e.g.	RB
cord-268347-xz6fptol	47	32	hydroxychloroquine	hydroxychloroquine	NNP
cord-268347-xz6fptol	47	33	/	/	SYM
cord-268347-xz6fptol	47	34	chloroquine	chloroquine	NNP
cord-268347-xz6fptol	47	35	,	,	,
cord-268347-xz6fptol	47	36	sulfasalazine	sulfasalazine	NNP
cord-268347-xz6fptol	47	37	,	,	,
cord-268347-xz6fptol	47	38	methotrexate	methotrexate	NNP
cord-268347-xz6fptol	47	39	,	,	,
cord-268347-xz6fptol	47	40	leflunomide	leflunomide	NNP
cord-268347-xz6fptol	47	41	,	,	,
cord-268347-xz6fptol	47	42	tacrolimus	tacrolimus	NN
cord-268347-xz6fptol	47	43	,	,	,
cord-268347-xz6fptol	47	44	ciclosporin	ciclosporin	NNP
cord-268347-xz6fptol	47	45	,	,	,
cord-268347-xz6fptol	47	46	mycophenolate	mycophenolate	NNP
cord-268347-xz6fptol	47	47	mofetil	mofetil	NNP
cord-268347-xz6fptol	47	48	and	and	CC
cord-268347-xz6fptol	47	49	azathioprine	azathioprine	NNP
cord-268347-xz6fptol	47	50	)	)	-RRB-
cord-268347-xz6fptol	47	51	,	,	,
cord-268347-xz6fptol	47	52	as	as	RB
cord-268347-xz6fptol	47	53	well	well	RB
cord-268347-xz6fptol	47	54	as	as	IN
cord-268347-xz6fptol	47	55	biological	biological	JJ
cord-268347-xz6fptol	47	56	DMARDs	dmard	NNS
cord-268347-xz6fptol	47	57	,	,	,
cord-268347-xz6fptol	47	58	such	such	JJ
cord-268347-xz6fptol	47	59	as	as	IN
cord-268347-xz6fptol	47	60	abatacept	abatacept	NNP
cord-268347-xz6fptol	47	61	,	,	,
cord-268347-xz6fptol	47	62	tocilizumab	tocilizumab	NNP
cord-268347-xz6fptol	47	63	and	and	CC
cord-268347-xz6fptol	47	64	JAK	JAK	NNP
cord-268347-xz6fptol	47	65	inhibitors	inhibitor	NNS
cord-268347-xz6fptol	47	66	(	(	-LRB-
cord-268347-xz6fptol	47	67	e.g.	e.g.	RB
cord-268347-xz6fptol	47	68	tofacitinib	tofacitinib	NNP
cord-268347-xz6fptol	47	69	,	,	,
cord-268347-xz6fptol	47	70	baricitinib	baricitinib	NNP
cord-268347-xz6fptol	47	71	and	and	CC
cord-268347-xz6fptol	47	72	upadacitinib	upadacitinib	NN
cord-268347-xz6fptol	47	73	)	)	-RRB-
cord-268347-xz6fptol	47	74	.	.	.
cord-268347-xz6fptol	48	1	Without	without	IN
cord-268347-xz6fptol	48	2	conclusive	conclusive	JJ
cord-268347-xz6fptol	48	3	proof	proof	NN
cord-268347-xz6fptol	48	4	from	from	IN
cord-268347-xz6fptol	48	5	clinical	clinical	JJ
cord-268347-xz6fptol	48	6	trials	trial	NNS
cord-268347-xz6fptol	48	7	,	,	,
cord-268347-xz6fptol	48	8	an	an	DT
cord-268347-xz6fptol	48	9	individualized	individualized	JJ
cord-268347-xz6fptol	48	10	approach	approach	NN
cord-268347-xz6fptol	48	11	to	to	IN
cord-268347-xz6fptol	48	12	adjusting	adjust	VBG
cord-268347-xz6fptol	48	13	DMARD	DMARD	NNP
cord-268347-xz6fptol	48	14	regimens	regimen	NNS
cord-268347-xz6fptol	48	15	in	in	IN
cord-268347-xz6fptol	48	16	patients	patient	NNS
cord-268347-xz6fptol	48	17	with	with	IN
cord-268347-xz6fptol	48	18	documented	documented	JJ
cord-268347-xz6fptol	48	19	or	or	CC
cord-268347-xz6fptol	48	20	presumptive	presumptive	JJ
cord-268347-xz6fptol	48	21	COVID-19	covid-19	NN
cord-268347-xz6fptol	48	22	seems	seem	VBZ
cord-268347-xz6fptol	48	23	prudent	prudent	JJ
cord-268347-xz6fptol	48	24	,	,	,
cord-268347-xz6fptol	48	25	with	with	IN
cord-268347-xz6fptol	48	26	specific	specific	JJ
cord-268347-xz6fptol	48	27	attention	attention	NN
cord-268347-xz6fptol	48	28	paid	pay	VBN
cord-268347-xz6fptol	48	29	to	to	IN
cord-268347-xz6fptol	48	30	severity	severity	NN
cord-268347-xz6fptol	48	31	of	of	IN
cord-268347-xz6fptol	48	32	illness	illness	NN
cord-268347-xz6fptol	48	33	.	.	.
cord-268347-xz6fptol	49	1	Management	management	NN
cord-268347-xz6fptol	49	2	practices	practice	NNS
cord-268347-xz6fptol	49	3	recommended	recommend	VBN
cord-268347-xz6fptol	49	4	by	by	IN
cord-268347-xz6fptol	49	5	various	various	JJ
cord-268347-xz6fptol	49	6	professional	professional	JJ
cord-268347-xz6fptol	49	7	societies	society	NNS
cord-268347-xz6fptol	49	8	of	of	IN
cord-268347-xz6fptol	49	9	rheumatology	rheumatology	NN
cord-268347-xz6fptol	49	10	can	can	MD
cord-268347-xz6fptol	49	11	be	be	VB
cord-268347-xz6fptol	49	12	useful	useful	JJ
cord-268347-xz6fptol	49	13	guidance	guidance	NN
cord-268347-xz6fptol	49	14	for	for	IN
cord-268347-xz6fptol	49	15	clinicians	clinician	NNS
cord-268347-xz6fptol	49	16	managing	manage	VBG
cord-268347-xz6fptol	49	17	documented	document	VBN
cord-268347-xz6fptol	49	18	or	or	CC
cord-268347-xz6fptol	49	19	presumptive	presumptive	JJ
cord-268347-xz6fptol	50	1	COVID-19	covid-19	JJ
cord-268347-xz6fptol	50	2	patients	patient	NNS
cord-268347-xz6fptol	50	3	with	with	IN
cord-268347-xz6fptol	50	4	systemic	systemic	JJ
cord-268347-xz6fptol	50	5	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	50	6	diseases	disease	NNS
cord-268347-xz6fptol	50	7	[	[	-LRB-
cord-268347-xz6fptol	50	8	22	22	CD
cord-268347-xz6fptol	50	9	]	]	-RRB-
cord-268347-xz6fptol	50	10	[	[	-LRB-
cord-268347-xz6fptol	50	11	23	23	CD
cord-268347-xz6fptol	50	12	]	]	-RRB-
cord-268347-xz6fptol	51	1	[	[	-LRB-
cord-268347-xz6fptol	51	2	24	24	CD
cord-268347-xz6fptol	51	3	]	]	-RRB-
cord-268347-xz6fptol	51	4	[	[	-LRB-
cord-268347-xz6fptol	51	5	25	25	CD
cord-268347-xz6fptol	51	6	]	]	-RRB-
cord-268347-xz6fptol	51	7	[	[	-LRB-
cord-268347-xz6fptol	51	8	26	26	CD
cord-268347-xz6fptol	51	9	]	]	-RRB-
cord-268347-xz6fptol	51	10	.	.	.
cord-268347-xz6fptol	52	1	The	the	DT
cord-268347-xz6fptol	52	2	decision	decision	NN
cord-268347-xz6fptol	52	3	to	to	IN
cord-268347-xz6fptol	52	4	either	either	DT
cord-268347-xz6fptol	52	5	continue/	continue/	NNP
cord-268347-xz6fptol	52	6	discontinue	discontinue	VB
cord-268347-xz6fptol	52	7	the	the	DT
cord-268347-xz6fptol	52	8	use	use	NN
cord-268347-xz6fptol	52	9	of	of	IN
cord-268347-xz6fptol	52	10	DMARDs	dmard	NNS
cord-268347-xz6fptol	52	11	should	should	MD
cord-268347-xz6fptol	52	12	be	be	VB
cord-268347-xz6fptol	52	13	made	make	VBN
cord-268347-xz6fptol	52	14	in	in	IN
cord-268347-xz6fptol	52	15	close	close	JJ
cord-268347-xz6fptol	52	16	consultation	consultation	NN
cord-268347-xz6fptol	52	17	with	with	IN
cord-268347-xz6fptol	52	18	the	the	DT
cord-268347-xz6fptol	52	19	experts	expert	NNS
cord-268347-xz6fptol	52	20	in	in	IN
cord-268347-xz6fptol	52	21	infectious	infectious	JJ
cord-268347-xz6fptol	52	22	disease	disease	NN
cord-268347-xz6fptol	52	23	and	and	CC
cord-268347-xz6fptol	52	24	critical	critical	JJ
cord-268347-xz6fptol	52	25	care	care	NN
cord-268347-xz6fptol	52	26	involved	involve	VBN
cord-268347-xz6fptol	52	27	in	in	IN
cord-268347-xz6fptol	52	28	the	the	DT
cord-268347-xz6fptol	52	29	management	management	NN
cord-268347-xz6fptol	52	30	of	of	IN
cord-268347-xz6fptol	52	31	the	the	DT
cord-268347-xz6fptol	52	32	patient	patient	NN
cord-268347-xz6fptol	52	33	's	's	POS
cord-268347-xz6fptol	52	34	acute	acute	JJ
cord-268347-xz6fptol	52	35	illness	illness	NN
cord-268347-xz6fptol	52	36	.	.	.
cord-268347-xz6fptol	53	1	Patients	patient	NNS
cord-268347-xz6fptol	53	2	receiving	receive	VBG
cord-268347-xz6fptol	53	3	antimalarials	antimalarial	NNS
cord-268347-xz6fptol	53	4	(	(	-LRB-
cord-268347-xz6fptol	53	5	hydroxychloroquine/	hydroxychloroquine/	NNP
cord-268347-xz6fptol	53	6	chloroquine	chloroquine	NN
cord-268347-xz6fptol	53	7	)	)	-RRB-
cord-268347-xz6fptol	53	8	may	may	MD
cord-268347-xz6fptol	53	9	continue	continue	VB
cord-268347-xz6fptol	53	10	these	these	DT
cord-268347-xz6fptol	53	11	agents	agent	NNS
cord-268347-xz6fptol	53	12	,	,	,
cord-268347-xz6fptol	53	13	although	although	IN
cord-268347-xz6fptol	53	14	they	-PRON-	PRP
cord-268347-xz6fptol	53	15	may	may	MD
cord-268347-xz6fptol	53	16	require	require	VB
cord-268347-xz6fptol	53	17	electrocardiographic	electrocardiographic	JJ
cord-268347-xz6fptol	53	18	screening	screening	NN
cord-268347-xz6fptol	53	19	and	and	CC
cord-268347-xz6fptol	53	20	monitoring	monitoring	NN
cord-268347-xz6fptol	53	21	given	give	VBN
cord-268347-xz6fptol	53	22	the	the	DT
cord-268347-xz6fptol	53	23	potential	potential	NN
cord-268347-xz6fptol	53	24	for	for	IN
cord-268347-xz6fptol	53	25	prolonged	prolonged	JJ
cord-268347-xz6fptol	53	26	QT	qt	NN
cord-268347-xz6fptol	53	27	interval	interval	NN
cord-268347-xz6fptol	53	28	and	and	CC
cord-268347-xz6fptol	53	29	possible	possible	JJ
cord-268347-xz6fptol	53	30	increased	increase	VBN
cord-268347-xz6fptol	53	31	risk	risk	NN
cord-268347-xz6fptol	53	32	of	of	IN
cord-268347-xz6fptol	53	33	cardiotoxicity	cardiotoxicity	NN
cord-268347-xz6fptol	53	34	in	in	IN
cord-268347-xz6fptol	53	35	the	the	DT
cord-268347-xz6fptol	53	36	context	context	NN
cord-268347-xz6fptol	53	37	of	of	IN
cord-268347-xz6fptol	53	38	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	53	39	.	.	.
cord-268347-xz6fptol	54	1	The	the	DT
cord-268347-xz6fptol	54	2	recommendation	recommendation	NN
cord-268347-xz6fptol	54	3	was	be	VBD
cord-268347-xz6fptol	54	4	based	base	VBN
cord-268347-xz6fptol	54	5	upon	upon	IN
cord-268347-xz6fptol	54	6	a	a	DT
cord-268347-xz6fptol	54	7	low	low	JJ
cord-268347-xz6fptol	54	8	risk	risk	NN
cord-268347-xz6fptol	54	9	of	of	IN
cord-268347-xz6fptol	54	10	serious	serious	JJ
cord-268347-xz6fptol	54	11	infection	infection	NN
cord-268347-xz6fptol	54	12	associated	associate	VBN
cord-268347-xz6fptol	54	13	with	with	IN
cord-268347-xz6fptol	54	14	hydroxychloroquine	hydroxychloroquine	NN
cord-268347-xz6fptol	54	15	/	/	SYM
cord-268347-xz6fptol	54	16	chloroquine	chloroquine	NN
cord-268347-xz6fptol	54	17	,	,	,
cord-268347-xz6fptol	54	18	as	as	RB
cord-268347-xz6fptol	54	19	well	well	RB
cord-268347-xz6fptol	54	20	as	as	IN
cord-268347-xz6fptol	54	21	the	the	DT
cord-268347-xz6fptol	54	22	potential	potential	JJ
cord-268347-xz6fptol	54	23	benefit	benefit	NN
cord-268347-xz6fptol	54	24	of	of	IN
cord-268347-xz6fptol	54	25	preventing	prevent	VBG
cord-268347-xz6fptol	54	26	a	a	DT
cord-268347-xz6fptol	54	27	flare	flare	NN
cord-268347-xz6fptol	54	28	-	-	HYPH
cord-268347-xz6fptol	54	29	up	up	NN
cord-268347-xz6fptol	54	30	from	from	IN
cord-268347-xz6fptol	54	31	systemic	systemic	JJ
cord-268347-xz6fptol	54	32	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	54	33	diseases	disease	NNS
cord-268347-xz6fptol	54	34	.	.	.
cord-268347-xz6fptol	55	1	Nonetheless	nonetheless	RB
cord-268347-xz6fptol	55	2	,	,	,
cord-268347-xz6fptol	55	3	concomitant	concomitant	JJ
cord-268347-xz6fptol	55	4	use	use	NN
cord-268347-xz6fptol	55	5	of	of	IN
cord-268347-xz6fptol	55	6	medications	medication	NNS
cord-268347-xz6fptol	55	7	that	that	WDT
cord-268347-xz6fptol	55	8	can	can	MD
cord-268347-xz6fptol	55	9	prolong	prolong	VB
cord-268347-xz6fptol	55	10	the	the	DT
cord-268347-xz6fptol	55	11	QT	qt	NN
cord-268347-xz6fptol	55	12	interval	interval	NN
cord-268347-xz6fptol	55	13	should	should	MD
cord-268347-xz6fptol	55	14	be	be	VB
cord-268347-xz6fptol	55	15	reduced	reduce	VBN
cord-268347-xz6fptol	55	16	,	,	,
cord-268347-xz6fptol	55	17	if	if	IN
cord-268347-xz6fptol	55	18	not	not	RB
cord-268347-xz6fptol	55	19	completely	completely	RB
cord-268347-xz6fptol	55	20	be	be	VB
cord-268347-xz6fptol	55	21	avoided	avoid	VBN
cord-268347-xz6fptol	55	22	,	,	,
cord-268347-xz6fptol	55	23	when	when	WRB
cord-268347-xz6fptol	55	24	the	the	DT
cord-268347-xz6fptol	55	25	decision	decision	NN
cord-268347-xz6fptol	55	26	is	be	VBZ
cord-268347-xz6fptol	55	27	made	make	VBN
cord-268347-xz6fptol	55	28	to	to	TO
cord-268347-xz6fptol	55	29	continue	continue	VB
cord-268347-xz6fptol	55	30	hydroxychloroquine	hydroxychloroquine	NN
cord-268347-xz6fptol	55	31	/	/	SYM
cord-268347-xz6fptol	55	32	chloroquine	chloroquine	NN
cord-268347-xz6fptol	55	33	treatment	treatment	NN
cord-268347-xz6fptol	55	34	.	.	.
cord-268347-xz6fptol	56	1	Sulfasalazine	Sulfasalazine	NNP
cord-268347-xz6fptol	56	2	,	,	,
cord-268347-xz6fptol	56	3	methotrexate	methotrexate	NNP
cord-268347-xz6fptol	56	4	,	,	,
cord-268347-xz6fptol	56	5	leflunomide	leflunomide	NN
cord-268347-xz6fptol	56	6	,	,	,
cord-268347-xz6fptol	56	7	immunosuppressants	immunosuppressant	NNS
cord-268347-xz6fptol	56	8	(	(	-LRB-
cord-268347-xz6fptol	56	9	e.g.	e.g.	NNP
cord-268347-xz6fptol	56	10	mycophenolate	mycophenolate	NNP
cord-268347-xz6fptol	56	11	mofetil	mofetil	NNP
cord-268347-xz6fptol	56	12	,	,	,
cord-268347-xz6fptol	56	13	azathioprine	azathioprine	NN
cord-268347-xz6fptol	56	14	)	)	-RRB-
cord-268347-xz6fptol	56	15	and	and	CC
cord-268347-xz6fptol	56	16	biological	biological	JJ
cord-268347-xz6fptol	56	17	agents	agent	NNS
cord-268347-xz6fptol	56	18	,	,	,
cord-268347-xz6fptol	56	19	other	other	JJ
cord-268347-xz6fptol	56	20	than	than	IN
cord-268347-xz6fptol	56	21	interleukin	interleukin	NN
cord-268347-xz6fptol	56	22	(	(	-LRB-
cord-268347-xz6fptol	56	23	IL)-6	IL)-6	NNP
cord-268347-xz6fptol	56	24	receptor	receptor	NN
cord-268347-xz6fptol	56	25	inhibitors	inhibitor	NNS
cord-268347-xz6fptol	56	26	and	and	CC
cord-268347-xz6fptol	56	27	JAK	JAK	NNP
cord-268347-xz6fptol	56	28	inhibitors	inhibitor	NNS
cord-268347-xz6fptol	56	29	,	,	,
cord-268347-xz6fptol	56	30	should	should	MD
cord-268347-xz6fptol	56	31	be	be	VB
cord-268347-xz6fptol	56	32	discontinued	discontinue	VBN
cord-268347-xz6fptol	56	33	temporarily	temporarily	RB
cord-268347-xz6fptol	56	34	in	in	IN
cord-268347-xz6fptol	56	35	patients	patient	NNS
cord-268347-xz6fptol	56	36	with	with	IN
cord-268347-xz6fptol	56	37	documented	documented	JJ
cord-268347-xz6fptol	56	38	or	or	CC
cord-268347-xz6fptol	56	39	presumptive	presumptive	JJ
cord-268347-xz6fptol	56	40	COVID-19	covid-19	NN
cord-268347-xz6fptol	56	41	.	.	.
cord-268347-xz6fptol	57	1	The	the	DT
cord-268347-xz6fptol	57	2	rationale	rationale	NN
cord-268347-xz6fptol	57	3	for	for	IN
cord-268347-xz6fptol	57	4	withholding	withhold	VBG
cord-268347-xz6fptol	57	5	sulfasalazine	sulfasalazine	NN
cord-268347-xz6fptol	57	6	in	in	IN
cord-268347-xz6fptol	57	7	the	the	DT
cord-268347-xz6fptol	57	8	context	context	NN
cord-268347-xz6fptol	57	9	of	of	IN
cord-268347-xz6fptol	57	10	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	57	11	is	be	VBZ
cord-268347-xz6fptol	57	12	due	due	JJ
cord-268347-xz6fptol	57	13	to	to	IN
cord-268347-xz6fptol	57	14	concerns	concern	NNS
cord-268347-xz6fptol	57	15	regarding	regard	VBG
cord-268347-xz6fptol	57	16	the	the	DT
cord-268347-xz6fptol	57	17	potential	potential	JJ
cord-268347-xz6fptol	57	18	confusion	confusion	NN
cord-268347-xz6fptol	57	19	of	of	IN
cord-268347-xz6fptol	57	20	adverse	adverse	JJ
cord-268347-xz6fptol	57	21	effects	effect	NNS
cord-268347-xz6fptol	57	22	from	from	IN
cord-268347-xz6fptol	57	23	sulfasalazine	sulfasalazine	NN
cord-268347-xz6fptol	57	24	(	(	-LRB-
cord-268347-xz6fptol	57	25	e.g.	e.g.	JJ
cord-268347-xz6fptol	57	26	gastrointestinal	gastrointestinal	JJ
cord-268347-xz6fptol	57	27	upset	upset	JJ
cord-268347-xz6fptol	57	28	,	,	,
cord-268347-xz6fptol	57	29	diarrhoea	diarrhoea	NN
cord-268347-xz6fptol	57	30	,	,	,
cord-268347-xz6fptol	57	31	hepatitis	hepatitis	NN
cord-268347-xz6fptol	57	32	,	,	,
cord-268347-xz6fptol	57	33	cytopenias	cytopenias	NNP
cord-268347-xz6fptol	57	34	and	and	CC
cord-268347-xz6fptol	57	35	pneumonitis	pneumonitis	NN
cord-268347-xz6fptol	57	36	)	)	-RRB-
cord-268347-xz6fptol	57	37	with	with	IN
cord-268347-xz6fptol	57	38	the	the	DT
cord-268347-xz6fptol	57	39	clinical	clinical	JJ
cord-268347-xz6fptol	57	40	manifestations	manifestation	NNS
cord-268347-xz6fptol	57	41	of	of	IN
cord-268347-xz6fptol	57	42	COVID-19	covid-19	NN
cord-268347-xz6fptol	57	43	.	.	.
cord-268347-xz6fptol	58	1	Theoretically	theoretically	RB
cord-268347-xz6fptol	58	2	,	,	,
cord-268347-xz6fptol	58	3	withholding	withhold	VBG
cord-268347-xz6fptol	58	4	sulfasalazine	sulfasalazine	NN
cord-268347-xz6fptol	58	5	for	for	IN
cord-268347-xz6fptol	58	6	up	up	IN
cord-268347-xz6fptol	58	7	to	to	TO
cord-268347-xz6fptol	58	8	2	2	CD
cord-268347-xz6fptol	58	9	or	or	CC
cord-268347-xz6fptol	58	10	3	3	CD
cord-268347-xz6fptol	58	11	weeks	week	NNS
cord-268347-xz6fptol	58	12	has	have	VBZ
cord-268347-xz6fptol	58	13	a	a	DT
cord-268347-xz6fptol	58	14	low	low	JJ
cord-268347-xz6fptol	58	15	likelihood	likelihood	NN
cord-268347-xz6fptol	58	16	of	of	IN
cord-268347-xz6fptol	58	17	resulting	result	VBG
cord-268347-xz6fptol	58	18	in	in	IN
cord-268347-xz6fptol	58	19	significant	significant	JJ
cord-268347-xz6fptol	58	20	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	58	21	disease	disease	NN
cord-268347-xz6fptol	58	22	flares	flare	NNS
cord-268347-xz6fptol	58	23	.	.	.
cord-268347-xz6fptol	59	1	Meanwhile	meanwhile	RB
cord-268347-xz6fptol	59	2	,	,	,
cord-268347-xz6fptol	59	3	temporary	temporary	JJ
cord-268347-xz6fptol	59	4	discontinuation	discontinuation	NN
cord-268347-xz6fptol	59	5	of	of	IN
cord-268347-xz6fptol	59	6	methotrexate	methotrexate	NNP
cord-268347-xz6fptol	59	7	,	,	,
cord-268347-xz6fptol	59	8	leflunomide	leflunomide	NN
cord-268347-xz6fptol	59	9	,	,	,
cord-268347-xz6fptol	59	10	immunosuppressants	immunosuppressant	NNS
cord-268347-xz6fptol	59	11	and	and	CC
cord-268347-xz6fptol	59	12	biological	biological	JJ
cord-268347-xz6fptol	59	13	agents	agent	NNS
cord-268347-xz6fptol	59	14	(	(	-LRB-
cord-268347-xz6fptol	59	15	other	other	JJ
cord-268347-xz6fptol	59	16	than	than	IN
cord-268347-xz6fptol	59	17	IL-6	IL-6	NNP
cord-268347-xz6fptol	59	18	receptor	receptor	NN
cord-268347-xz6fptol	59	19	and	and	CC
cord-268347-xz6fptol	59	20	JAK	JAK	NNP
cord-268347-xz6fptol	59	21	inhibitors	inhibitor	NNS
cord-268347-xz6fptol	59	22	)	)	-RRB-
cord-268347-xz6fptol	59	23	is	be	VBZ
cord-268347-xz6fptol	59	24	mainly	mainly	RB
cord-268347-xz6fptol	59	25	related	relate	VBN
cord-268347-xz6fptol	59	26	to	to	IN
cord-268347-xz6fptol	59	27	the	the	DT
cord-268347-xz6fptol	59	28	growing	grow	VBG
cord-268347-xz6fptol	59	29	concerns	concern	NNS
cord-268347-xz6fptol	59	30	over	over	IN
cord-268347-xz6fptol	59	31	possible	possible	JJ
cord-268347-xz6fptol	59	32	impairment	impairment	NN
cord-268347-xz6fptol	59	33	in	in	IN
cord-268347-xz6fptol	59	34	the	the	DT
cord-268347-xz6fptol	59	35	host	host	NN
cord-268347-xz6fptol	59	36	defence	defence	NN
cord-268347-xz6fptol	59	37	mechanism	mechanism	NN
cord-268347-xz6fptol	59	38	against	against	IN
cord-268347-xz6fptol	59	39	SARS	SARS	NNP
cord-268347-xz6fptol	59	40	-	-	HYPH
cord-268347-xz6fptol	59	41	CoV-2	CoV-2	NNP
cord-268347-xz6fptol	59	42	and	and	CC
cord-268347-xz6fptol	59	43	the	the	DT
cord-268347-xz6fptol	59	44	risk	risk	NN
cord-268347-xz6fptol	59	45	of	of	IN
cord-268347-xz6fptol	59	46	secondary	secondary	JJ
cord-268347-xz6fptol	59	47	bacterial	bacterial	JJ
cord-268347-xz6fptol	59	48	or	or	CC
cord-268347-xz6fptol	59	49	opportunistic	opportunistic	JJ
cord-268347-xz6fptol	59	50	infections	infection	NNS
cord-268347-xz6fptol	59	51	.	.	.
cord-268347-xz6fptol	60	1	Likewise	likewise	RB
cord-268347-xz6fptol	60	2	,	,	,
cord-268347-xz6fptol	60	3	the	the	DT
cord-268347-xz6fptol	60	4	theoretical	theoretical	JJ
cord-268347-xz6fptol	60	5	risk	risk	NN
cord-268347-xz6fptol	60	6	of	of	IN
cord-268347-xz6fptol	60	7	a	a	DT
cord-268347-xz6fptol	60	8	flare	flare	NN
cord-268347-xz6fptol	60	9	-	-	HYPH
cord-268347-xz6fptol	60	10	up	up	NN
cord-268347-xz6fptol	60	11	from	from	IN
cord-268347-xz6fptol	60	12	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	60	13	diseases	disease	NNS
cord-268347-xz6fptol	60	14	is	be	VBZ
cord-268347-xz6fptol	60	15	likely	likely	JJ
cord-268347-xz6fptol	60	16	to	to	TO
cord-268347-xz6fptol	60	17	be	be	VB
cord-268347-xz6fptol	60	18	relatively	relatively	RB
cord-268347-xz6fptol	60	19	low	low	JJ
cord-268347-xz6fptol	60	20	during	during	IN
cord-268347-xz6fptol	60	21	the	the	DT
cord-268347-xz6fptol	60	22	limited	limited	JJ
cord-268347-xz6fptol	60	23	period	period	NN
cord-268347-xz6fptol	60	24	in	in	IN
cord-268347-xz6fptol	60	25	which	which	WDT
cord-268347-xz6fptol	60	26	DMARDs	dmard	NNS
cord-268347-xz6fptol	60	27	are	be	VBP
cord-268347-xz6fptol	60	28	being	be	VBG
cord-268347-xz6fptol	60	29	withheld	withhold	VBN
cord-268347-xz6fptol	60	30	,	,	,
cord-268347-xz6fptol	60	31	while	while	IN
cord-268347-xz6fptol	60	32	the	the	DT
cord-268347-xz6fptol	60	33	risk	risk	NN
cord-268347-xz6fptol	60	34	of	of	IN
cord-268347-xz6fptol	60	35	secondary	secondary	JJ
cord-268347-xz6fptol	60	36	bacterial	bacterial	JJ
cord-268347-xz6fptol	60	37	or	or	CC
cord-268347-xz6fptol	60	38	opportunistic	opportunistic	JJ
cord-268347-xz6fptol	60	39	infections	infection	NNS
cord-268347-xz6fptol	60	40	should	should	MD
cord-268347-xz6fptol	60	41	not	not	RB
cord-268347-xz6fptol	60	42	be	be	VB
cord-268347-xz6fptol	60	43	ignored	ignore	VBN
cord-268347-xz6fptol	60	44	,	,	,
cord-268347-xz6fptol	60	45	as	as	IN
cord-268347-xz6fptol	60	46	it	-PRON-	PRP
cord-268347-xz6fptol	60	47	is	be	VBZ
cord-268347-xz6fptol	60	48	now	now	RB
cord-268347-xz6fptol	60	49	recognized	recognize	VBN
cord-268347-xz6fptol	60	50	that	that	IN
cord-268347-xz6fptol	60	51	a	a	DT
cord-268347-xz6fptol	60	52	substantial	substantial	JJ
cord-268347-xz6fptol	60	53	proportion	proportion	NN
cord-268347-xz6fptol	60	54	of	of	IN
cord-268347-xz6fptol	60	55	patients	patient	NNS
cord-268347-xz6fptol	60	56	with	with	IN
cord-268347-xz6fptol	60	57	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	60	58	may	may	MD
cord-268347-xz6fptol	60	59	develop	develop	VB
cord-268347-xz6fptol	60	60	secondary	secondary	JJ
cord-268347-xz6fptol	60	61	bacterial	bacterial	JJ
cord-268347-xz6fptol	60	62	pneumonia	pneumonia	NN
cord-268347-xz6fptol	60	63	[	[	-LRB-
cord-268347-xz6fptol	60	64	1	1	CD
cord-268347-xz6fptol	60	65	]	]	-RRB-
cord-268347-xz6fptol	60	66	.	.	.
cord-268347-xz6fptol	61	1	On	on	IN
cord-268347-xz6fptol	61	2	the	the	DT
cord-268347-xz6fptol	61	3	other	other	JJ
cord-268347-xz6fptol	61	4	hand	hand	NN
cord-268347-xz6fptol	61	5	,	,	,
cord-268347-xz6fptol	61	6	IL-6	IL-6	NNP
cord-268347-xz6fptol	61	7	receptor	receptor	NN
cord-268347-xz6fptol	61	8	inhibitors	inhibitor	NNS
cord-268347-xz6fptol	61	9	(	(	-LRB-
cord-268347-xz6fptol	61	10	e.g.	e.g.	IN
cord-268347-xz6fptol	61	11	tocilizumab	tocilizumab	NNP
cord-268347-xz6fptol	61	12	and	and	CC
cord-268347-xz6fptol	61	13	sarilumab	sarilumab	NNP
cord-268347-xz6fptol	61	14	)	)	-RRB-
cord-268347-xz6fptol	61	15	may	may	MD
cord-268347-xz6fptol	61	16	be	be	VB
cord-268347-xz6fptol	61	17	continued	continue	VBN
cord-268347-xz6fptol	61	18	in	in	IN
cord-268347-xz6fptol	61	19	selected	select	VBN
cord-268347-xz6fptol	61	20	patients	patient	NNS
cord-268347-xz6fptol	61	21	,	,	,
cord-268347-xz6fptol	61	22	particularly	particularly	RB
cord-268347-xz6fptol	61	23	those	those	DT
cord-268347-xz6fptol	61	24	in	in	IN
cord-268347-xz6fptol	61	25	whom	whom	WP
cord-268347-xz6fptol	61	26	cytokine	cytokine	NN
cord-268347-xz6fptol	61	27	storm	storm	NN
cord-268347-xz6fptol	61	28	syndrome	syndrome	NN
cord-268347-xz6fptol	61	29	is	be	VBZ
cord-268347-xz6fptol	61	30	impending	impending	JJ
cord-268347-xz6fptol	61	31	,	,	,
cord-268347-xz6fptol	61	32	preferably	preferably	RB
cord-268347-xz6fptol	61	33	in	in	IN
cord-268347-xz6fptol	61	34	clinical	clinical	JJ
cord-268347-xz6fptol	61	35	trial	trial	NN
cord-268347-xz6fptol	61	36	settings	setting	NNS
cord-268347-xz6fptol	61	37	,	,	,
cord-268347-xz6fptol	61	38	given	give	VBN
cord-268347-xz6fptol	61	39	the	the	DT
cord-268347-xz6fptol	61	40	potential	potential	JJ
cord-268347-xz6fptol	61	41	benefit	benefit	NN
cord-268347-xz6fptol	61	42	of	of	IN
cord-268347-xz6fptol	61	43	IL-6	IL-6	NNP
cord-268347-xz6fptol	61	44	inhibitors	inhibitor	NNS
cord-268347-xz6fptol	61	45	in	in	IN
cord-268347-xz6fptol	61	46	COVID-19	covid-19	CD
cord-268347-xz6fptol	61	47	patients	patient	NNS
cord-268347-xz6fptol	61	48	who	who	WP
cord-268347-xz6fptol	61	49	develop	develop	VBP
cord-268347-xz6fptol	61	50	an	an	DT
cord-268347-xz6fptol	61	51	intense	intense	JJ
cord-268347-xz6fptol	61	52	inflammatory	inflammatory	JJ
cord-268347-xz6fptol	61	53	state	state	NN
cord-268347-xz6fptol	61	54	;	;	:
cord-268347-xz6fptol	61	55	however	however	RB
cord-268347-xz6fptol	61	56	,	,	,
cord-268347-xz6fptol	61	57	conclusive	conclusive	JJ
cord-268347-xz6fptol	61	58	evidence	evidence	NN
cord-268347-xz6fptol	61	59	on	on	IN
cord-268347-xz6fptol	61	60	their	-PRON-	PRP$
cord-268347-xz6fptol	61	61	efficacy	efficacy	NN
cord-268347-xz6fptol	61	62	remains	remain	VBZ
cord-268347-xz6fptol	61	63	to	to	TO
cord-268347-xz6fptol	61	64	be	be	VB
cord-268347-xz6fptol	61	65	elucidated	elucidate	VBN
cord-268347-xz6fptol	61	66	[	[	-LRB-
cord-268347-xz6fptol	61	67	27	27	CD
cord-268347-xz6fptol	61	68	]	]	-RRB-
cord-268347-xz6fptol	61	69	[	[	-LRB-
cord-268347-xz6fptol	61	70	28	28	CD
cord-268347-xz6fptol	61	71	]	]	-RRB-
cord-268347-xz6fptol	61	72	[	[	-LRB-
cord-268347-xz6fptol	61	73	29	29	CD
cord-268347-xz6fptol	61	74	]	]	-RRB-
cord-268347-xz6fptol	61	75	[	[	-LRB-
cord-268347-xz6fptol	61	76	30	30	CD
cord-268347-xz6fptol	61	77	]	]	-RRB-
cord-268347-xz6fptol	61	78	[	[	-LRB-
cord-268347-xz6fptol	61	79	31	31	CD
cord-268347-xz6fptol	61	80	]	]	-RRB-
cord-268347-xz6fptol	61	81	[	[	-LRB-
cord-268347-xz6fptol	61	82	32	32	CD
cord-268347-xz6fptol	61	83	]	]	-RRB-
cord-268347-xz6fptol	61	84	[	[	-LRB-
cord-268347-xz6fptol	61	85	33	33	CD
cord-268347-xz6fptol	61	86	]	]	-RRB-
cord-268347-xz6fptol	61	87	.	.	.
cord-268347-xz6fptol	62	1	There	there	EX
cord-268347-xz6fptol	62	2	are	be	VBP
cord-268347-xz6fptol	62	3	very	very	RB
cord-268347-xz6fptol	62	4	limited	limited	JJ
cord-268347-xz6fptol	62	5	data	datum	NNS
cord-268347-xz6fptol	62	6	to	to	TO
cord-268347-xz6fptol	62	7	address	address	VB
cord-268347-xz6fptol	62	8	the	the	DT
cord-268347-xz6fptol	62	9	issue	issue	NN
cord-268347-xz6fptol	62	10	on	on	IN
cord-268347-xz6fptol	62	11	the	the	DT
cord-268347-xz6fptol	62	12	optimal	optimal	JJ
cord-268347-xz6fptol	62	13	time	time	NN
cord-268347-xz6fptol	62	14	to	to	TO
cord-268347-xz6fptol	62	15	resume	resume	VB
cord-268347-xz6fptol	62	16	DMARDs	dmard	NNS
cord-268347-xz6fptol	62	17	after	after	IN
cord-268347-xz6fptol	62	18	a	a	DT
cord-268347-xz6fptol	62	19	diagnosis	diagnosis	NN
cord-268347-xz6fptol	62	20	of	of	IN
cord-268347-xz6fptol	62	21	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	62	22	,	,	,
cord-268347-xz6fptol	62	23	but	but	CC
cord-268347-xz6fptol	62	24	we	-PRON-	PRP
cord-268347-xz6fptol	62	25	think	think	VBP
cord-268347-xz6fptol	62	26	it	-PRON-	PRP
cord-268347-xz6fptol	62	27	should	should	MD
cord-268347-xz6fptol	62	28	be	be	VB
cord-268347-xz6fptol	62	29	reasonable	reasonable	JJ
cord-268347-xz6fptol	62	30	to	to	TO
cord-268347-xz6fptol	62	31	resume	resume	VB
cord-268347-xz6fptol	62	32	when	when	WRB
cord-268347-xz6fptol	62	33	patients	patient	NNS
cord-268347-xz6fptol	62	34	are	be	VBP
cord-268347-xz6fptol	62	35	no	no	RB
cord-268347-xz6fptol	62	36	longer	long	RBR
cord-268347-xz6fptol	62	37	symptomatic	symptomatic	JJ
cord-268347-xz6fptol	62	38	and	and	CC
cord-268347-xz6fptol	62	39	at	at	IN
cord-268347-xz6fptol	62	40	least	least	JJS
cord-268347-xz6fptol	62	41	2	2	CD
cord-268347-xz6fptol	62	42	weeks	week	NNS
cord-268347-xz6fptol	62	43	have	have	VBP
cord-268347-xz6fptol	62	44	passed	pass	VBN
cord-268347-xz6fptol	62	45	since	since	IN
cord-268347-xz6fptol	62	46	the	the	DT
cord-268347-xz6fptol	62	47	documentation	documentation	NN
cord-268347-xz6fptol	62	48	of	of	IN
cord-268347-xz6fptol	62	49	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	62	50	.	.	.
cord-268347-xz6fptol	63	1	More	More	JJR
cord-268347-xz6fptol	63	2	information	information	NN
cord-268347-xz6fptol	63	3	regarding	regard	VBG
cord-268347-xz6fptol	63	4	how	how	WRB
cord-268347-xz6fptol	63	5	long	long	RB
cord-268347-xz6fptol	63	6	COVID-19	covid-19	CD
cord-268347-xz6fptol	63	7	patients	patient	NNS
cord-268347-xz6fptol	63	8	remain	remain	VBP
cord-268347-xz6fptol	63	9	infectious	infectious	JJ
cord-268347-xz6fptol	63	10	is	be	VBZ
cord-268347-xz6fptol	63	11	needed	need	VBN
cord-268347-xz6fptol	63	12	.	.	.
cord-268347-xz6fptol	64	1	Without	without	IN
cord-268347-xz6fptol	64	2	conclusive	conclusive	JJ
cord-268347-xz6fptol	64	3	data	datum	NNS
cord-268347-xz6fptol	64	4	as	as	IN
cord-268347-xz6fptol	64	5	yet	yet	RB
cord-268347-xz6fptol	64	6	,	,	,
cord-268347-xz6fptol	64	7	there	there	EX
cord-268347-xz6fptol	64	8	is	be	VBZ
cord-268347-xz6fptol	64	9	no	no	DT
cord-268347-xz6fptol	64	10	'	'	``
cord-268347-xz6fptol	64	11	one	one	CD
cord-268347-xz6fptol	64	12	size	size	NN
cord-268347-xz6fptol	64	13	fits	fit	VBZ
cord-268347-xz6fptol	64	14	all	all	DT
cord-268347-xz6fptol	64	15	'	'	''
cord-268347-xz6fptol	64	16	approach	approach	NN
cord-268347-xz6fptol	64	17	regarding	regard	VBG
cord-268347-xz6fptol	64	18	the	the	DT
cord-268347-xz6fptol	64	19	time	time	NN
cord-268347-xz6fptol	64	20	to	to	IN
cord-268347-xz6fptol	64	21	resumption	resumption	NN
cord-268347-xz6fptol	64	22	of	of	IN
cord-268347-xz6fptol	64	23	DMARDs	dmard	NNS
cord-268347-xz6fptol	64	24	;	;	:
cord-268347-xz6fptol	64	25	therefore	therefore	RB
cord-268347-xz6fptol	64	26	,	,	,
cord-268347-xz6fptol	64	27	the	the	DT
cord-268347-xz6fptol	64	28	approach	approach	NN
cord-268347-xz6fptol	64	29	should	should	MD
cord-268347-xz6fptol	64	30	be	be	VB
cord-268347-xz6fptol	64	31	individualized	individualize	VBN
cord-268347-xz6fptol	64	32	,	,	,
cord-268347-xz6fptol	64	33	preferably	preferably	RB
cord-268347-xz6fptol	64	34	based	base	VBN
cord-268347-xz6fptol	64	35	on	on	IN
cord-268347-xz6fptol	64	36	the	the	DT
cord-268347-xz6fptol	64	37	severity	severity	NN
cord-268347-xz6fptol	64	38	of	of	IN
cord-268347-xz6fptol	64	39	illness	illness	NN
cord-268347-xz6fptol	64	40	.	.	.
cord-268347-xz6fptol	65	1	It	-PRON-	PRP
cord-268347-xz6fptol	65	2	has	have	VBZ
cord-268347-xz6fptol	65	3	been	be	VBN
cord-268347-xz6fptol	65	4	demonstrated	demonstrate	VBN
cord-268347-xz6fptol	65	5	that	that	IN
cord-268347-xz6fptol	65	6	replication	replication	NN
cord-268347-xz6fptol	65	7	-	-	HYPH
cord-268347-xz6fptol	65	8	competent	competent	JJ
cord-268347-xz6fptol	65	9	(	(	-LRB-
cord-268347-xz6fptol	65	10	live/	live/	CD
cord-268347-xz6fptol	65	11	viable	viable	JJ
cord-268347-xz6fptol	65	12	)	)	-RRB-
cord-268347-xz6fptol	66	1	SARS	SARS	NNP
cord-268347-xz6fptol	66	2	-	-	HYPH
cord-268347-xz6fptol	66	3	CoV-2	CoV-2	NNP
cord-268347-xz6fptol	66	4	has	have	VBZ
cord-268347-xz6fptol	66	5	not	not	RB
cord-268347-xz6fptol	66	6	been	be	VBN
cord-268347-xz6fptol	66	7	recovered	recover	VBN
cord-268347-xz6fptol	66	8	up	up	RP
cord-268347-xz6fptol	66	9	to	to	TO
cord-268347-xz6fptol	66	10	9	9	CD
cord-268347-xz6fptol	66	11	days	day	NNS
cord-268347-xz6fptol	66	12	from	from	IN
cord-268347-xz6fptol	66	13	symptom	symptom	NN
cord-268347-xz6fptol	66	14	onset	onset	NN
cord-268347-xz6fptol	66	15	in	in	IN
cord-268347-xz6fptol	66	16	patients	patient	NNS
cord-268347-xz6fptol	66	17	with	with	IN
cord-268347-xz6fptol	66	18	mild	mild	NN
cord-268347-xz6fptol	66	19	-	-	HYPH
cord-268347-xz6fptol	66	20	to	to	IN
cord-268347-xz6fptol	66	21	-	-	HYPH
cord-268347-xz6fptol	66	22	moderate	moderate	JJ
cord-268347-xz6fptol	66	23	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	66	24	.	.	.
cord-268347-xz6fptol	67	1	To	to	TO
cord-268347-xz6fptol	67	2	illustrate	illustrate	VB
cord-268347-xz6fptol	67	3	,	,	,
cord-268347-xz6fptol	67	4	in	in	IN
cord-268347-xz6fptol	67	5	a	a	DT
cord-268347-xz6fptol	67	6	small	small	JJ
cord-268347-xz6fptol	67	7	observational	observational	JJ
cord-268347-xz6fptol	67	8	study	study	NN
cord-268347-xz6fptol	67	9	in	in	IN
cord-268347-xz6fptol	67	10	nine	nine	CD
cord-268347-xz6fptol	67	11	COVID-19	covid-19	CD
cord-268347-xz6fptol	67	12	patients	patient	NNS
cord-268347-xz6fptol	67	13	[	[	-LRB-
cord-268347-xz6fptol	67	14	34	34	CD
cord-268347-xz6fptol	67	15	]	]	-RRB-
cord-268347-xz6fptol	67	16	,	,	,
cord-268347-xz6fptol	67	17	seroconversion	seroconversion	NN
cord-268347-xz6fptol	67	18	was	be	VBD
cord-268347-xz6fptol	67	19	detected	detect	VBN
cord-268347-xz6fptol	67	20	in	in	IN
cord-268347-xz6fptol	67	21	all	all	DT
cord-268347-xz6fptol	67	22	patients	patient	NNS
cord-268347-xz6fptol	67	23	after	after	IN
cord-268347-xz6fptol	67	24	2	2	CD
cord-268347-xz6fptol	67	25	weeks	week	NNS
cord-268347-xz6fptol	67	26	,	,	,
cord-268347-xz6fptol	67	27	while	while	IN
cord-268347-xz6fptol	67	28	viral	viral	JJ
cord-268347-xz6fptol	67	29	loads	load	NNS
cord-268347-xz6fptol	67	30	progressively	progressively	RB
cord-268347-xz6fptol	67	31	decreased	decrease	VBD
cord-268347-xz6fptol	67	32	,	,	,
cord-268347-xz6fptol	67	33	and	and	CC
cord-268347-xz6fptol	67	34	the	the	DT
cord-268347-xz6fptol	67	35	live	live	JJ
cord-268347-xz6fptol	67	36	virus	virus	NN
cord-268347-xz6fptol	67	37	was	be	VBD
cord-268347-xz6fptol	67	38	unable	unable	JJ
cord-268347-xz6fptol	67	39	to	to	TO
cord-268347-xz6fptol	67	40	be	be	VB
cord-268347-xz6fptol	67	41	isolated	isolate	VBN
cord-268347-xz6fptol	67	42	8	8	CD
cord-268347-xz6fptol	67	43	days	day	NNS
cord-268347-xz6fptol	67	44	after	after	IN
cord-268347-xz6fptol	67	45	symptom	symptom	NN
cord-268347-xz6fptol	67	46	onset	onset	NN
cord-268347-xz6fptol	67	47	.	.	.
cord-268347-xz6fptol	68	1	Similarly	similarly	RB
cord-268347-xz6fptol	68	2	,	,	,
cord-268347-xz6fptol	68	3	in	in	IN
cord-268347-xz6fptol	68	4	a	a	DT
cord-268347-xz6fptol	68	5	cross	cross	JJ
cord-268347-xz6fptol	68	6	-	-	JJ
cord-268347-xz6fptol	68	7	sectional	sectional	JJ
cord-268347-xz6fptol	68	8	study	study	NN
cord-268347-xz6fptol	68	9	that	that	WDT
cord-268347-xz6fptol	68	10	analysed	analyse	VBD
cord-268347-xz6fptol	68	11	90	90	CD
cord-268347-xz6fptol	68	12	SARS	SARS	NNP
cord-268347-xz6fptol	68	13	-	-	HYPH
cord-268347-xz6fptol	68	14	CoV-2-positive	cov-2-positive	JJ
cord-268347-xz6fptol	68	15	samples	sample	NNS
cord-268347-xz6fptol	68	16	that	that	WDT
cord-268347-xz6fptol	68	17	ranged	range	VBD
cord-268347-xz6fptol	68	18	from	from	IN
cord-268347-xz6fptol	68	19	the	the	DT
cord-268347-xz6fptol	68	20	day	day	NN
cord-268347-xz6fptol	68	21	of	of	IN
cord-268347-xz6fptol	68	22	symptom	symptom	NN
cord-268347-xz6fptol	68	23	onset	onset	NN
cord-268347-xz6fptol	68	24	to	to	IN
cord-268347-xz6fptol	68	25	21	21	CD
cord-268347-xz6fptol	68	26	days	day	NNS
cord-268347-xz6fptol	68	27	post	post	JJ
cord-268347-xz6fptol	68	28	-	-	JJ
cord-268347-xz6fptol	68	29	symptom	symptom	JJ
cord-268347-xz6fptol	68	30	onset	onset	NN
cord-268347-xz6fptol	68	31	,	,	,
cord-268347-xz6fptol	68	32	positive	positive	JJ
cord-268347-xz6fptol	68	33	cultures	culture	NNS
cord-268347-xz6fptol	68	34	were	be	VBD
cord-268347-xz6fptol	68	35	only	only	RB
cord-268347-xz6fptol	68	36	observed	observe	VBN
cord-268347-xz6fptol	68	37	up	up	IN
cord-268347-xz6fptol	68	38	to	to	TO
cord-268347-xz6fptol	68	39	8	8	CD
cord-268347-xz6fptol	68	40	days	day	NNS
cord-268347-xz6fptol	68	41	post	post	JJ
cord-268347-xz6fptol	68	42	-	-	JJ
cord-268347-xz6fptol	68	43	symptom	symptom	JJ
cord-268347-xz6fptol	68	44	onset	onset	NN
cord-268347-xz6fptol	68	45	[	[	-LRB-
cord-268347-xz6fptol	68	46	35	35	CD
cord-268347-xz6fptol	68	47	]	]	-RRB-
cord-268347-xz6fptol	68	48	.	.	.
cord-268347-xz6fptol	69	1	In	in	IN
cord-268347-xz6fptol	69	2	another	another	DT
cord-268347-xz6fptol	69	3	study	study	NN
cord-268347-xz6fptol	69	4	,	,	,
cord-268347-xz6fptol	69	5	isolation	isolation	NN
cord-268347-xz6fptol	69	6	of	of	IN
cord-268347-xz6fptol	69	7	viable	viable	JJ
cord-268347-xz6fptol	69	8	SARS	SARS	NNP
cord-268347-xz6fptol	69	9	-	-	HYPH
cord-268347-xz6fptol	69	10	CoV-2	CoV-2	NNP
cord-268347-xz6fptol	69	11	from	from	IN
cord-268347-xz6fptol	69	12	nasopharyngeal	nasopharyngeal	JJ
cord-268347-xz6fptol	69	13	and	and	CC
cord-268347-xz6fptol	69	14	oropharyngeal	oropharyngeal	JJ
cord-268347-xz6fptol	69	15	swabs	swab	NNS
cord-268347-xz6fptol	69	16	in	in	IN
cord-268347-xz6fptol	69	17	31	31	CD
cord-268347-xz6fptol	69	18	COVID-19	covid-19	CD
cord-268347-xz6fptol	69	19	patients	patient	NNS
cord-268347-xz6fptol	69	20	was	be	VBD
cord-268347-xz6fptol	69	21	possible	possible	JJ
cord-268347-xz6fptol	69	22	only	only	RB
cord-268347-xz6fptol	69	23	up	up	IN
cord-268347-xz6fptol	69	24	to	to	TO
cord-268347-xz6fptol	69	25	9	9	CD
cord-268347-xz6fptol	69	26	days	day	NNS
cord-268347-xz6fptol	69	27	after	after	IN
cord-268347-xz6fptol	69	28	symptom	symptom	NN
cord-268347-xz6fptol	69	29	onset	onset	NN
cord-268347-xz6fptol	69	30	[	[	-LRB-
cord-268347-xz6fptol	69	31	36	36	CD
cord-268347-xz6fptol	69	32	]	]	-RRB-
cord-268347-xz6fptol	69	33	.	.	.
cord-268347-xz6fptol	70	1	Recovery	recovery	NN
cord-268347-xz6fptol	70	2	of	of	IN
cord-268347-xz6fptol	70	3	replication	replication	NN
cord-268347-xz6fptol	70	4	-	-	HYPH
cord-268347-xz6fptol	70	5	competent	competent	JJ
cord-268347-xz6fptol	70	6	SARS	SARS	NNP
cord-268347-xz6fptol	70	7	-	-	HYPH
cord-268347-xz6fptol	70	8	CoV-2	CoV-2	NNP
cord-268347-xz6fptol	70	9	10	10	CD
cord-268347-xz6fptol	70	10	-	-	SYM
cord-268347-xz6fptol	70	11	20	20	CD
cord-268347-xz6fptol	70	12	days	day	NNS
cord-268347-xz6fptol	70	13	after	after	IN
cord-268347-xz6fptol	70	14	symptom	symptom	NN
cord-268347-xz6fptol	70	15	onset	onset	NN
cord-268347-xz6fptol	70	16	has	have	VBZ
cord-268347-xz6fptol	70	17	been	be	VBN
cord-268347-xz6fptol	70	18	documented	document	VBN
cord-268347-xz6fptol	70	19	in	in	IN
cord-268347-xz6fptol	70	20	some	some	DT
cord-268347-xz6fptol	70	21	patients	patient	NNS
cord-268347-xz6fptol	70	22	with	with	IN
cord-268347-xz6fptol	70	23	a	a	DT
cord-268347-xz6fptol	70	24	severe	severe	JJ
cord-268347-xz6fptol	70	25	course	course	NN
cord-268347-xz6fptol	70	26	of	of	IN
cord-268347-xz6fptol	70	27	COVID-19	covid-19	NN
cord-268347-xz6fptol	70	28	complicated	complicate	VBN
cord-268347-xz6fptol	70	29	by	by	IN
cord-268347-xz6fptol	70	30	an	an	DT
cord-268347-xz6fptol	70	31	immunocompromised	immunocompromised	JJ
cord-268347-xz6fptol	70	32	state	state	NN
cord-268347-xz6fptol	70	33	[	[	-LRB-
cord-268347-xz6fptol	70	34	37	37	CD
cord-268347-xz6fptol	70	35	]	]	-RRB-
cord-268347-xz6fptol	70	36	.	.	.
cord-268347-xz6fptol	71	1	In	in	IN
cord-268347-xz6fptol	71	2	a	a	DT
cord-268347-xz6fptol	71	3	series	series	NN
cord-268347-xz6fptol	71	4	of	of	IN
cord-268347-xz6fptol	71	5	129	129	CD
cord-268347-xz6fptol	71	6	COVID-19	covid-19	CD
cord-268347-xz6fptol	71	7	patients	patient	NNS
cord-268347-xz6fptol	71	8	with	with	IN
cord-268347-xz6fptol	71	9	a	a	DT
cord-268347-xz6fptol	71	10	severe	severe	JJ
cord-268347-xz6fptol	71	11	or	or	CC
cord-268347-xz6fptol	71	12	critical	critical	JJ
cord-268347-xz6fptol	71	13	illness	illness	NN
cord-268347-xz6fptol	71	14	,	,	,
cord-268347-xz6fptol	71	15	of	of	IN
cord-268347-xz6fptol	71	16	whom	whom	WP
cord-268347-xz6fptol	71	17	30	30	CD
cord-268347-xz6fptol	71	18	were	be	VBD
cord-268347-xz6fptol	71	19	immunocompromised	immunocompromised	JJ
cord-268347-xz6fptol	71	20	,	,	,
cord-268347-xz6fptol	71	21	viable	viable	JJ
cord-268347-xz6fptol	71	22	SARS	SARS	NNP
cord-268347-xz6fptol	71	23	-	-	HYPH
cord-268347-xz6fptol	71	24	CoV-2	CoV-2	NNP
cord-268347-xz6fptol	71	25	was	be	VBD
cord-268347-xz6fptol	71	26	detected	detect	VBN
cord-268347-xz6fptol	71	27	in	in	IN
cord-268347-xz6fptol	71	28	a	a	DT
cord-268347-xz6fptol	71	29	single	single	JJ
cord-268347-xz6fptol	71	30	patient	patient	NN
cord-268347-xz6fptol	71	31	up	up	IN
cord-268347-xz6fptol	71	32	to	to	TO
cord-268347-xz6fptol	71	33	20	20	CD
cord-268347-xz6fptol	71	34	days	day	NNS
cord-268347-xz6fptol	71	35	after	after	IN
cord-268347-xz6fptol	71	36	onset	onset	NN
cord-268347-xz6fptol	71	37	of	of	IN
cord-268347-xz6fptol	71	38	symptoms	symptom	NNS
cord-268347-xz6fptol	71	39	[	[	-LRB-
cord-268347-xz6fptol	71	40	37	37	CD
cord-268347-xz6fptol	71	41	]	]	-RRB-
cord-268347-xz6fptol	71	42	.	.	.
cord-268347-xz6fptol	72	1	Nevertheless	nevertheless	RB
cord-268347-xz6fptol	72	2	,	,	,
cord-268347-xz6fptol	72	3	it	-PRON-	PRP
cord-268347-xz6fptol	72	4	was	be	VBD
cord-268347-xz6fptol	72	5	estimated	estimate	VBN
cord-268347-xz6fptol	72	6	that	that	IN
cord-268347-xz6fptol	72	7	95	95	CD
cord-268347-xz6fptol	72	8	%	%	NN
cord-268347-xz6fptol	72	9	of	of	IN
cord-268347-xz6fptol	72	10	the	the	DT
cord-268347-xz6fptol	72	11	samples	sample	NNS
cord-268347-xz6fptol	72	12	no	no	RB
cord-268347-xz6fptol	72	13	longer	long	RBR
cord-268347-xz6fptol	72	14	yielded	yield	VBD
cord-268347-xz6fptol	72	15	a	a	DT
cord-268347-xz6fptol	72	16	replication	replication	NN
cord-268347-xz6fptol	72	17	-	-	HYPH
cord-268347-xz6fptol	72	18	competent	competent	JJ
cord-268347-xz6fptol	72	19	virus	virus	NN
cord-268347-xz6fptol	72	20	15	15	CD
cord-268347-xz6fptol	72	21	days	day	NNS
cord-268347-xz6fptol	72	22	following	follow	VBG
cord-268347-xz6fptol	72	23	symptom	symptom	NN
cord-268347-xz6fptol	72	24	onset	onset	NN
cord-268347-xz6fptol	72	25	[	[	-LRB-
cord-268347-xz6fptol	72	26	37	37	CD
cord-268347-xz6fptol	72	27	]	]	-RRB-
cord-268347-xz6fptol	72	28	.	.	.
cord-268347-xz6fptol	73	1	In	in	IN
cord-268347-xz6fptol	73	2	conclusion	conclusion	NN
cord-268347-xz6fptol	73	3	,	,	,
cord-268347-xz6fptol	73	4	we	-PRON-	PRP
cord-268347-xz6fptol	73	5	have	have	VBP
cord-268347-xz6fptol	73	6	more	more	JJR
cord-268347-xz6fptol	73	7	questions	question	NNS
cord-268347-xz6fptol	73	8	than	than	IN
cord-268347-xz6fptol	73	9	answers	answer	NNS
cord-268347-xz6fptol	73	10	in	in	IN
cord-268347-xz6fptol	73	11	the	the	DT
cord-268347-xz6fptol	73	12	management	management	NN
cord-268347-xz6fptol	73	13	of	of	IN
cord-268347-xz6fptol	73	14	rheumatology	rheumatology	NN
cord-268347-xz6fptol	73	15	patients	patient	NNS
cord-268347-xz6fptol	73	16	in	in	IN
cord-268347-xz6fptol	73	17	the	the	DT
cord-268347-xz6fptol	73	18	context	context	NN
cord-268347-xz6fptol	73	19	of	of	IN
cord-268347-xz6fptol	73	20	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	73	21	.	.	.
cord-268347-xz6fptol	74	1	Future	future	JJ
cord-268347-xz6fptol	74	2	studies	study	NNS
cord-268347-xz6fptol	74	3	should	should	MD
cord-268347-xz6fptol	74	4	aim	aim	VB
cord-268347-xz6fptol	74	5	to	to	TO
cord-268347-xz6fptol	74	6	answer	answer	VB
cord-268347-xz6fptol	74	7	the	the	DT
cord-268347-xz6fptol	74	8	following	follow	VBG
cord-268347-xz6fptol	74	9	questions	question	NNS
cord-268347-xz6fptol	74	10	raised	raise	VBN
cord-268347-xz6fptol	74	11	in	in	IN
cord-268347-xz6fptol	74	12	our	-PRON-	PRP$
cord-268347-xz6fptol	74	13	discussion	discussion	NN
cord-268347-xz6fptol	74	14	:	:	:
cord-268347-xz6fptol	74	15	•	•	NNP
cord-268347-xz6fptol	74	16	Does	do	VBZ
cord-268347-xz6fptol	74	17	the	the	DT
cord-268347-xz6fptol	74	18	presence	presence	NN
cord-268347-xz6fptol	74	19	of	of	IN
cord-268347-xz6fptol	74	20	systemic	systemic	JJ
cord-268347-xz6fptol	74	21	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	74	22	disease	disease	NN
cord-268347-xz6fptol	74	23	increase	increase	VB
cord-268347-xz6fptol	74	24	the	the	DT
cord-268347-xz6fptol	74	25	risk	risk	NN
cord-268347-xz6fptol	74	26	of	of	IN
cord-268347-xz6fptol	74	27	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	74	28	acquisition	acquisition	NN
cord-268347-xz6fptol	74	29	or	or	CC
cord-268347-xz6fptol	74	30	a	a	DT
cord-268347-xz6fptol	74	31	worse	bad	JJR
cord-268347-xz6fptol	74	32	prognosis	prognosis	NN
cord-268347-xz6fptol	74	33	from	from	IN
cord-268347-xz6fptol	74	34	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	74	35	?	?	.
cord-268347-xz6fptol	74	36	•	•	XX
cord-268347-xz6fptol	75	1	Does	do	VBZ
cord-268347-xz6fptol	75	2	the	the	DT
cord-268347-xz6fptol	75	3	baseline	baseline	JJ
cord-268347-xz6fptol	75	4	use	use	NN
cord-268347-xz6fptol	75	5	of	of	IN
cord-268347-xz6fptol	75	6	rheumatologic	rheumatologic	JJ
cord-268347-xz6fptol	75	7	treatment	treatment	NN
cord-268347-xz6fptol	75	8	,	,	,
cord-268347-xz6fptol	75	9	including	include	VBG
cord-268347-xz6fptol	75	10	biological	biological	JJ
cord-268347-xz6fptol	75	11	and	and	CC
cord-268347-xz6fptol	75	12	non	non	JJ
cord-268347-xz6fptol	75	13	-	-	JJ
cord-268347-xz6fptol	75	14	biological	biological	JJ
cord-268347-xz6fptol	75	15	agents	agent	NNS
cord-268347-xz6fptol	75	16	,	,	,
cord-268347-xz6fptol	75	17	increase	increase	VB
cord-268347-xz6fptol	75	18	the	the	DT
cord-268347-xz6fptol	75	19	risk	risk	NN
cord-268347-xz6fptol	75	20	of	of	IN
cord-268347-xz6fptol	75	21	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	75	22	acquisition	acquisition	NN
cord-268347-xz6fptol	75	23	or	or	CC
cord-268347-xz6fptol	75	24	adverse	adverse	JJ
cord-268347-xz6fptol	75	25	outcomes	outcome	NNS
cord-268347-xz6fptol	75	26	?	?	.
cord-268347-xz6fptol	76	1	•	•	NNP
cord-268347-xz6fptol	77	1	Do	do	VBP
cord-268347-xz6fptol	77	2	the	the	DT
cord-268347-xz6fptol	77	3	benefits	benefit	NNS
cord-268347-xz6fptol	77	4	of	of	IN
cord-268347-xz6fptol	77	5	initiation	initiation	NN
cord-268347-xz6fptol	77	6	or	or	CC
cord-268347-xz6fptol	77	7	continuation	continuation	NN
cord-268347-xz6fptol	77	8	of	of	IN
cord-268347-xz6fptol	77	9	pharmacological	pharmacological	JJ
cord-268347-xz6fptol	77	10	agents	agent	NNS
cord-268347-xz6fptol	77	11	for	for	IN
cord-268347-xz6fptol	77	12	the	the	DT
cord-268347-xz6fptol	77	13	management	management	NN
cord-268347-xz6fptol	77	14	of	of	IN
cord-268347-xz6fptol	77	15	(	(	-LRB-
cord-268347-xz6fptol	77	16	newly	newly	RB
cord-268347-xz6fptol	77	17	)	)	-RRB-
cord-268347-xz6fptol	77	18	diagnosed	diagnose	VBN
cord-268347-xz6fptol	77	19	systemic	systemic	JJ
cord-268347-xz6fptol	77	20	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	77	21	diseases	disease	NNS
cord-268347-xz6fptol	77	22	outweigh	outweigh	VBP
cord-268347-xz6fptol	77	23	the	the	DT
cord-268347-xz6fptol	77	24	risks	risk	NNS
cord-268347-xz6fptol	77	25	of	of	IN
cord-268347-xz6fptol	77	26	COVID-19	covid-19	JJ
cord-268347-xz6fptol	77	27	acquisition	acquisition	NN
cord-268347-xz6fptol	77	28	?	?	.
cord-268347-xz6fptol	78	1	•	•	NNP
cord-268347-xz6fptol	79	1	Should	Should	MD
cord-268347-xz6fptol	79	2	pharmacological	pharmacological	JJ
cord-268347-xz6fptol	79	3	regimens	regimen	NNS
cord-268347-xz6fptol	79	4	for	for	IN
cord-268347-xz6fptol	79	5	the	the	DT
cord-268347-xz6fptol	79	6	management	management	NN
cord-268347-xz6fptol	79	7	of	of	IN
cord-268347-xz6fptol	79	8	systemic	systemic	JJ
cord-268347-xz6fptol	79	9	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	79	10	diseases	disease	NNS
cord-268347-xz6fptol	79	11	be	be	VB
cord-268347-xz6fptol	79	12	adjusted	adjust	VBN
cord-268347-xz6fptol	79	13	(	(	-LRB-
cord-268347-xz6fptol	79	14	continued/	continued/	NN
cord-268347-xz6fptol	79	15	discontinued	discontinue	VBN
cord-268347-xz6fptol	79	16	)	)	-RRB-
cord-268347-xz6fptol	79	17	in	in	IN
cord-268347-xz6fptol	79	18	patients	patient	NNS
cord-268347-xz6fptol	79	19	with	with	IN
cord-268347-xz6fptol	79	20	documented	documented	JJ
cord-268347-xz6fptol	79	21	or	or	CC
cord-268347-xz6fptol	79	22	presumptive	presumptive	JJ
cord-268347-xz6fptol	79	23	COVID-19	covid-19	NN
cord-268347-xz6fptol	79	24	?	?	.
cord-268347-xz6fptol	80	1	•	•	NNP
cord-268347-xz6fptol	81	1	When	when	WRB
cord-268347-xz6fptol	81	2	is	be	VBZ
cord-268347-xz6fptol	81	3	the	the	DT
cord-268347-xz6fptol	81	4	optimal	optimal	JJ
cord-268347-xz6fptol	81	5	time	time	NN
cord-268347-xz6fptol	81	6	for	for	IN
cord-268347-xz6fptol	81	7	the	the	DT
cord-268347-xz6fptol	81	8	resumption	resumption	NN
cord-268347-xz6fptol	81	9	of	of	IN
cord-268347-xz6fptol	81	10	antirheumatic	antirheumatic	JJ
cord-268347-xz6fptol	81	11	drugs	drug	NNS
cord-268347-xz6fptol	81	12	after	after	IN
cord-268347-xz6fptol	81	13	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	81	14	?	?	.
cord-268347-xz6fptol	82	1	•	•	NNP
cord-268347-xz6fptol	83	1	Be	be	VB
cord-268347-xz6fptol	83	2	aware	aware	JJ
cord-268347-xz6fptol	83	3	that	that	IN
cord-268347-xz6fptol	83	4	the	the	DT
cord-268347-xz6fptol	83	5	presence	presence	NN
cord-268347-xz6fptol	83	6	of	of	IN
cord-268347-xz6fptol	83	7	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	83	8	disease	disease	NN
cord-268347-xz6fptol	83	9	alone	alone	RB
cord-268347-xz6fptol	83	10	is	be	VBZ
cord-268347-xz6fptol	83	11	not	not	RB
cord-268347-xz6fptol	83	12	yet	yet	RB
cord-268347-xz6fptol	83	13	associated	associate	VBN
cord-268347-xz6fptol	83	14	with	with	IN
cord-268347-xz6fptol	83	15	an	an	DT
cord-268347-xz6fptol	83	16	increased	increase	VBN
cord-268347-xz6fptol	83	17	risk	risk	NN
cord-268347-xz6fptol	83	18	for	for	IN
cord-268347-xz6fptol	83	19	acquiring	acquire	VBG
cord-268347-xz6fptol	83	20	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	83	21	.	.	.
cord-268347-xz6fptol	84	1	•	•	NNP
cord-268347-xz6fptol	84	2	Individualize	individualize	VB
cord-268347-xz6fptol	84	3	adjustments	adjustment	NNS
cord-268347-xz6fptol	84	4	to	to	IN
cord-268347-xz6fptol	84	5	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	84	6	medications	medication	NNS
cord-268347-xz6fptol	84	7	in	in	IN
cord-268347-xz6fptol	84	8	patients	patient	NNS
cord-268347-xz6fptol	84	9	with	with	IN
cord-268347-xz6fptol	84	10	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	84	11	,	,	,
cord-268347-xz6fptol	84	12	taking	take	VBG
cord-268347-xz6fptol	84	13	infection	infection	NN
cord-268347-xz6fptol	84	14	severity	severity	NN
cord-268347-xz6fptol	84	15	into	into	IN
cord-268347-xz6fptol	84	16	consideration	consideration	NN
cord-268347-xz6fptol	84	17	.	.	.
cord-268347-xz6fptol	85	1	•	•	NNP
cord-268347-xz6fptol	86	1	In	in	IN
cord-268347-xz6fptol	86	2	the	the	DT
cord-268347-xz6fptol	86	3	absence	absence	NN
cord-268347-xz6fptol	86	4	of	of	IN
cord-268347-xz6fptol	86	5	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	86	6	,	,	,
cord-268347-xz6fptol	86	7	generally	generally	RB
cord-268347-xz6fptol	86	8	follow	follow	VBP
cord-268347-xz6fptol	86	9	the	the	DT
cord-268347-xz6fptol	86	10	usual	usual	JJ
cord-268347-xz6fptol	86	11	treatment	treatment	NN
cord-268347-xz6fptol	86	12	approaches	approach	NNS
cord-268347-xz6fptol	86	13	and	and	CC
cord-268347-xz6fptol	86	14	recommendations	recommendation	NNS
cord-268347-xz6fptol	86	15	for	for	IN
cord-268347-xz6fptol	86	16	managing	manage	VBG
cord-268347-xz6fptol	86	17	patients	patient	NNS
cord-268347-xz6fptol	86	18	with	with	IN
cord-268347-xz6fptol	86	19	newly	newly	RB
cord-268347-xz6fptol	86	20	diagnosed	diagnose	VBN
cord-268347-xz6fptol	86	21	or	or	CC
cord-268347-xz6fptol	86	22	stable	stable	JJ
cord-268347-xz6fptol	86	23	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	86	24	disease	disease	NN
cord-268347-xz6fptol	86	25	.	.	.
cord-268347-xz6fptol	87	1	Author	author	NN
cord-268347-xz6fptol	87	2	contributions	contribution	NNS
cord-268347-xz6fptol	88	1	CSK	CSK	NNP
cord-268347-xz6fptol	88	2	and	and	CC
cord-268347-xz6fptol	88	3	SSH	SSH	NNP
cord-268347-xz6fptol	88	4	contributed	contribute	VBD
cord-268347-xz6fptol	88	5	equally	equally	RB
cord-268347-xz6fptol	88	6	to	to	IN
cord-268347-xz6fptol	88	7	the	the	DT
cord-268347-xz6fptol	88	8	writing	writing	NN
cord-268347-xz6fptol	88	9	of	of	IN
cord-268347-xz6fptol	88	10	this	this	DT
cord-268347-xz6fptol	88	11	manuscript	manuscript	NN
cord-268347-xz6fptol	88	12	.	.	.
cord-268347-xz6fptol	89	1	The	the	DT
cord-268347-xz6fptol	89	2	authors	author	NNS
cord-268347-xz6fptol	89	3	have	have	VBP
cord-268347-xz6fptol	89	4	no	no	DT
cord-268347-xz6fptol	89	5	potential	potential	JJ
cord-268347-xz6fptol	89	6	conflict	conflict	NN
cord-268347-xz6fptol	89	7	of	of	IN
cord-268347-xz6fptol	89	8	interest	interest	NN
cord-268347-xz6fptol	89	9	to	to	TO
cord-268347-xz6fptol	89	10	declare	declare	VB
cord-268347-xz6fptol	89	11	.	.	.
cord-268347-xz6fptol	90	1	Funding	funding	NN
cord-268347-xz6fptol	91	1	No	no	DT
cord-268347-xz6fptol	91	2	funding	funding	NN
cord-268347-xz6fptol	91	3	was	be	VBD
cord-268347-xz6fptol	91	4	received	receive	VBN
cord-268347-xz6fptol	91	5	.	.	.
cord-268347-xz6fptol	92	1	Ethics	ethic	NNS
cord-268347-xz6fptol	92	2	approval	approval	NN
cord-268347-xz6fptol	92	3	,	,	,
cord-268347-xz6fptol	92	4	Consent	Consent	NNP
cord-268347-xz6fptol	92	5	to	to	TO
cord-268347-xz6fptol	92	6	participate	participate	VB
cord-268347-xz6fptol	92	7	,	,	,
cord-268347-xz6fptol	92	8	Consent	Consent	NNP
cord-268347-xz6fptol	92	9	for	for	IN
cord-268347-xz6fptol	92	10	publication	publication	NN
cord-268347-xz6fptol	92	11	,	,	,
cord-268347-xz6fptol	92	12	Availability	availability	NN
cord-268347-xz6fptol	92	13	of	of	IN
cord-268347-xz6fptol	92	14	data	datum	NNS
cord-268347-xz6fptol	92	15	and	and	CC
cord-268347-xz6fptol	92	16	materials	material	NNS
cord-268347-xz6fptol	92	17	and	and	CC
cord-268347-xz6fptol	92	18	Code	Code	NNP
cord-268347-xz6fptol	92	19	availability	availability	NN
cord-268347-xz6fptol	93	1	None	none	NN
cord-268347-xz6fptol	93	2	applicable	applicable	JJ
cord-268347-xz6fptol	93	3	.	.	.
cord-268347-xz6fptol	94	1	Clinical	clinical	JJ
cord-268347-xz6fptol	94	2	course	course	NN
cord-268347-xz6fptol	94	3	and	and	CC
cord-268347-xz6fptol	94	4	risk	risk	NN
cord-268347-xz6fptol	94	5	factors	factor	NNS
cord-268347-xz6fptol	94	6	for	for	IN
cord-268347-xz6fptol	94	7	mortality	mortality	NN
cord-268347-xz6fptol	94	8	of	of	IN
cord-268347-xz6fptol	94	9	adult	adult	NN
cord-268347-xz6fptol	94	10	inpatients	inpatient	NNS
cord-268347-xz6fptol	94	11	with	with	IN
cord-268347-xz6fptol	94	12	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	94	13	in	in	IN
cord-268347-xz6fptol	94	14	Wuhan	Wuhan	NNP
cord-268347-xz6fptol	94	15	,	,	,
cord-268347-xz6fptol	94	16	China	China	NNP
cord-268347-xz6fptol	94	17	:	:	:
cord-268347-xz6fptol	95	1	a	a	DT
cord-268347-xz6fptol	95	2	retrospective	retrospective	JJ
cord-268347-xz6fptol	95	3	cohort	cohort	NN
cord-268347-xz6fptol	95	4	study	study	NN
cord-268347-xz6fptol	95	5	Characteristics	characteristic	NNS
cord-268347-xz6fptol	95	6	of	of	IN
cord-268347-xz6fptol	95	7	and	and	CC
cord-268347-xz6fptol	95	8	important	important	JJ
cord-268347-xz6fptol	95	9	lessons	lesson	NNS
cord-268347-xz6fptol	95	10	from	from	IN
cord-268347-xz6fptol	95	11	the	the	DT
cord-268347-xz6fptol	95	12	coronavirus	coronavirus	NN
cord-268347-xz6fptol	95	13	disease	disease	NN
cord-268347-xz6fptol	95	14	2019	2019	CD
cord-268347-xz6fptol	95	15	(	(	-LRB-
cord-268347-xz6fptol	95	16	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	95	17	)	)	-RRB-
cord-268347-xz6fptol	95	18	outbreak	outbreak	NN
cord-268347-xz6fptol	95	19	in	in	IN
cord-268347-xz6fptol	95	20	China	China	NNP
cord-268347-xz6fptol	95	21	:	:	:
cord-268347-xz6fptol	95	22	summary	summary	NN
cord-268347-xz6fptol	95	23	of	of	IN
cord-268347-xz6fptol	95	24	a	a	DT
cord-268347-xz6fptol	95	25	report	report	NN
cord-268347-xz6fptol	95	26	of	of	IN
cord-268347-xz6fptol	95	27	72	72	CD
cord-268347-xz6fptol	95	28	314	314	CD
cord-268347-xz6fptol	95	29	cases	case	NNS
cord-268347-xz6fptol	95	30	from	from	IN
cord-268347-xz6fptol	95	31	the	the	DT
cord-268347-xz6fptol	95	32	Chinese	Chinese	NNP
cord-268347-xz6fptol	95	33	Center	Center	NNP
cord-268347-xz6fptol	95	34	for	for	IN
cord-268347-xz6fptol	95	35	Disease	Disease	NNP
cord-268347-xz6fptol	95	36	Control	Control	NNP
cord-268347-xz6fptol	95	37	and	and	CC
cord-268347-xz6fptol	95	38	Prevention	Prevention	NNP
cord-268347-xz6fptol	96	1	Covid-19	Covid-19	NNP
cord-268347-xz6fptol	96	2	in	in	IN
cord-268347-xz6fptol	96	3	immunemediated	immunemediated	JJ
cord-268347-xz6fptol	96	4	inflammatory	inflammatory	JJ
cord-268347-xz6fptol	96	5	disease	disease	NN
cord-268347-xz6fptol	96	6	:	:	:
cord-268347-xz6fptol	96	7	case	case	NN
cord-268347-xz6fptol	96	8	series	series	NN
cord-268347-xz6fptol	96	9	from	from	IN
cord-268347-xz6fptol	96	10	New	New	NNP
cord-268347-xz6fptol	96	11	York	York	NNP
cord-268347-xz6fptol	96	12	Co	co	NN
cord-268347-xz6fptol	96	13	-	-	NN
cord-268347-xz6fptol	96	14	morbidity	morbidity	NN
cord-268347-xz6fptol	96	15	in	in	IN
cord-268347-xz6fptol	96	16	rheumatoid	rheumatoid	NN
cord-268347-xz6fptol	96	17	arthritis	arthritis	NN
cord-268347-xz6fptol	96	18	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	96	19	pneumonia	pneumonia	NN
cord-268347-xz6fptol	96	20	in	in	IN
cord-268347-xz6fptol	96	21	a	a	DT
cord-268347-xz6fptol	96	22	large	large	JJ
cord-268347-xz6fptol	96	23	cohort	cohort	NN
cord-268347-xz6fptol	96	24	of	of	IN
cord-268347-xz6fptol	96	25	patients	patient	NNS
cord-268347-xz6fptol	96	26	treated	treat	VBN
cord-268347-xz6fptol	96	27	with	with	IN
cord-268347-xz6fptol	96	28	biological	biological	JJ
cord-268347-xz6fptol	96	29	and	and	CC
cord-268347-xz6fptol	96	30	targeted	target	VBN
cord-268347-xz6fptol	96	31	synthetic	synthetic	JJ
cord-268347-xz6fptol	96	32	antirheumatic	antirheumatic	JJ
cord-268347-xz6fptol	96	33	drugs	drug	NNS
cord-268347-xz6fptol	96	34	Rheumatic	rheumatic	JJ
cord-268347-xz6fptol	96	35	diseases	disease	NNS
cord-268347-xz6fptol	96	36	in	in	IN
cord-268347-xz6fptol	96	37	intensive	intensive	JJ
cord-268347-xz6fptol	96	38	care	care	NN
cord-268347-xz6fptol	96	39	unit	unit	NN
cord-268347-xz6fptol	96	40	patients	patient	NNS
cord-268347-xz6fptol	96	41	with	with	IN
cord-268347-xz6fptol	96	42	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	96	43	Dealing	deal	VBG
cord-268347-xz6fptol	96	44	with	with	IN
cord-268347-xz6fptol	96	45	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	96	46	in	in	IN
cord-268347-xz6fptol	96	47	a	a	DT
cord-268347-xz6fptol	96	48	pediatric	pediatric	JJ
cord-268347-xz6fptol	96	49	rheumatology	rheumatology	NN
cord-268347-xz6fptol	96	50	unit	unit	NN
cord-268347-xz6fptol	96	51	in	in	IN
cord-268347-xz6fptol	96	52	Italy	Italy	NNP
cord-268347-xz6fptol	96	53	Management	Management	NNP
cord-268347-xz6fptol	96	54	of	of	IN
cord-268347-xz6fptol	96	55	pediatric	pediatric	JJ
cord-268347-xz6fptol	96	56	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	96	57	patients	patient	NNS
cord-268347-xz6fptol	96	58	in	in	IN
cord-268347-xz6fptol	96	59	Kazakhstan	Kazakhstan	NNP
cord-268347-xz6fptol	96	60	during	during	IN
cord-268347-xz6fptol	96	61	the	the	DT
cord-268347-xz6fptol	96	62	coronavirus	coronavirus	NN
cord-268347-xz6fptol	96	63	disease	disease	NN
cord-268347-xz6fptol	96	64	2019	2019	CD
cord-268347-xz6fptol	96	65	(	(	-LRB-
cord-268347-xz6fptol	96	66	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	96	67	)	)	-RRB-
cord-268347-xz6fptol	96	68	pandemic	pandemic	NN
cord-268347-xz6fptol	96	69	Cardiovascular	cardiovascular	JJ
cord-268347-xz6fptol	96	70	comorbidity	comorbidity	NN
cord-268347-xz6fptol	96	71	in	in	IN
cord-268347-xz6fptol	96	72	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	96	73	diseases	disease	NNS
cord-268347-xz6fptol	96	74	Prevention	prevention	NN
cord-268347-xz6fptol	96	75	and	and	CC
cord-268347-xz6fptol	96	76	management	management	NN
cord-268347-xz6fptol	96	77	of	of	IN
cord-268347-xz6fptol	96	78	co	co	NNS
cord-268347-xz6fptol	96	79	-	-	NNS
cord-268347-xz6fptol	96	80	morbidities	morbidity	NNS
cord-268347-xz6fptol	96	81	in	in	IN
cord-268347-xz6fptol	96	82	SLE	SLE	NNP
cord-268347-xz6fptol	96	83	Comorbidities	Comorbidities	NNP
cord-268347-xz6fptol	96	84	associated	associate	VBN
cord-268347-xz6fptol	96	85	with	with	IN
cord-268347-xz6fptol	96	86	psoriatic	psoriatic	JJ
cord-268347-xz6fptol	96	87	arthritis	arthritis	NN
cord-268347-xz6fptol	96	88	:	:	:
cord-268347-xz6fptol	97	1	review	review	VB
cord-268347-xz6fptol	97	2	and	and	CC
cord-268347-xz6fptol	97	3	update	update	VB
cord-268347-xz6fptol	97	4	Diabetes	diabetes	NN
cord-268347-xz6fptol	97	5	and	and	CC
cord-268347-xz6fptol	97	6	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	97	7	diseases	disease	NNS
cord-268347-xz6fptol	97	8	Obesity	obesity	NN
cord-268347-xz6fptol	97	9	in	in	IN
cord-268347-xz6fptol	97	10	psoriatic	psoriatic	JJ
cord-268347-xz6fptol	97	11	arthritis	arthritis	NN
cord-268347-xz6fptol	97	12	:	:	:
cord-268347-xz6fptol	97	13	comparative	comparative	JJ
cord-268347-xz6fptol	97	14	prevalence	prevalence	NN
cord-268347-xz6fptol	97	15	and	and	CC
cord-268347-xz6fptol	97	16	associated	associated	JJ
cord-268347-xz6fptol	97	17	factors	factor	NNS
cord-268347-xz6fptol	97	18	.	.	.
cord-268347-xz6fptol	98	1	Medicine	Medicine	NNP
cord-268347-xz6fptol	98	2	(	(	-LRB-
cord-268347-xz6fptol	98	3	Baltimore	Baltimore	NNP
cord-268347-xz6fptol	98	4	)	)	-RRB-
cord-268347-xz6fptol	98	5	Hypertension	hypertension	NN
cord-268347-xz6fptol	98	6	in	in	IN
cord-268347-xz6fptol	98	7	rheumatoid	rheumatoid	NN
cord-268347-xz6fptol	98	8	arthritis	arthritis	NN
cord-268347-xz6fptol	98	9	Risk	Risk	NNP
cord-268347-xz6fptol	98	10	of	of	IN
cord-268347-xz6fptol	98	11	cardiovascular	cardiovascular	JJ
cord-268347-xz6fptol	98	12	mortality	mortality	NN
cord-268347-xz6fptol	98	13	in	in	IN
cord-268347-xz6fptol	98	14	patients	patient	NNS
cord-268347-xz6fptol	98	15	with	with	IN
cord-268347-xz6fptol	98	16	rheumatoid	rheumatoid	NN
cord-268347-xz6fptol	98	17	arthritis	arthritis	NN
cord-268347-xz6fptol	98	18	:	:	:
cord-268347-xz6fptol	98	19	a	a	DT
cord-268347-xz6fptol	98	20	meta	meta	JJ
cord-268347-xz6fptol	98	21	-	-	HYPH
cord-268347-xz6fptol	98	22	analysis	analysis	NN
cord-268347-xz6fptol	98	23	of	of	IN
cord-268347-xz6fptol	98	24	observational	observational	JJ
cord-268347-xz6fptol	98	25	studies	study	NNS
cord-268347-xz6fptol	99	1	The	the	DT
cord-268347-xz6fptol	99	2	epidemiology	epidemiology	NN
cord-268347-xz6fptol	99	3	of	of	IN
cord-268347-xz6fptol	99	4	atherosclerotic	atherosclerotic	JJ
cord-268347-xz6fptol	99	5	cardiovascular	cardiovascular	JJ
cord-268347-xz6fptol	99	6	disease	disease	NN
cord-268347-xz6fptol	99	7	among	among	IN
cord-268347-xz6fptol	99	8	patients	patient	NNS
cord-268347-xz6fptol	99	9	with	with	IN
cord-268347-xz6fptol	99	10	SLE	SLE	NNP
cord-268347-xz6fptol	99	11	:	:	:
cord-268347-xz6fptol	99	12	a	a	DT
cord-268347-xz6fptol	99	13	systematic	systematic	JJ
cord-268347-xz6fptol	99	14	review	review	NN
cord-268347-xz6fptol	99	15	Infections	infection	NNS
cord-268347-xz6fptol	99	16	in	in	IN
cord-268347-xz6fptol	99	17	rheumatoid	rheumatoid	NN
cord-268347-xz6fptol	99	18	arthritis	arthritis	NN
cord-268347-xz6fptol	99	19	Safety	Safety	NNP
cord-268347-xz6fptol	99	20	of	of	IN
cord-268347-xz6fptol	99	21	synthetic	synthetic	JJ
cord-268347-xz6fptol	99	22	and	and	CC
cord-268347-xz6fptol	99	23	biological	biological	JJ
cord-268347-xz6fptol	99	24	DMARDs	dmard	NNS
cord-268347-xz6fptol	99	25	:	:	:
cord-268347-xz6fptol	99	26	a	a	DT
cord-268347-xz6fptol	99	27	systematic	systematic	JJ
cord-268347-xz6fptol	99	28	literature	literature	NN
cord-268347-xz6fptol	99	29	review	review	NN
cord-268347-xz6fptol	99	30	informing	inform	VBG
cord-268347-xz6fptol	99	31	the	the	DT
cord-268347-xz6fptol	99	32	2019	2019	CD
cord-268347-xz6fptol	99	33	update	update	NN
cord-268347-xz6fptol	99	34	of	of	IN
cord-268347-xz6fptol	99	35	the	the	DT
cord-268347-xz6fptol	99	36	EULAR	EULAR	NNP
cord-268347-xz6fptol	99	37	recommendations	recommendation	NNS
cord-268347-xz6fptol	99	38	for	for	IN
cord-268347-xz6fptol	99	39	the	the	DT
cord-268347-xz6fptol	99	40	management	management	NN
cord-268347-xz6fptol	99	41	of	of	IN
cord-268347-xz6fptol	99	42	rheumatoid	rheumatoid	NNP
cord-268347-xz6fptol	99	43	arthritis	arthritis	NN
cord-268347-xz6fptol	99	44	Biologics	Biologics	NNPS
cord-268347-xz6fptol	99	45	for	for	IN
cord-268347-xz6fptol	99	46	the	the	DT
cord-268347-xz6fptol	99	47	treatment	treatment	NN
cord-268347-xz6fptol	99	48	of	of	IN
cord-268347-xz6fptol	99	49	juvenile	juvenile	JJ
cord-268347-xz6fptol	99	50	idiopathic	idiopathic	JJ
cord-268347-xz6fptol	99	51	arthritis	arthritis	NN
cord-268347-xz6fptol	99	52	Biologics	biologic	NNS
cord-268347-xz6fptol	99	53	increase	increase	VBP
cord-268347-xz6fptol	99	54	the	the	DT
cord-268347-xz6fptol	99	55	risk	risk	NN
cord-268347-xz6fptol	99	56	of	of	IN
cord-268347-xz6fptol	99	57	SARS	SARS	NNP
cord-268347-xz6fptol	99	58	-	-	HYPH
cord-268347-xz6fptol	99	59	CoV-2	CoV-2	NNP
cord-268347-xz6fptol	99	60	infection	infection	NN
cord-268347-xz6fptol	99	61	and	and	CC
cord-268347-xz6fptol	99	62	hospitalization	hospitalization	NN
cord-268347-xz6fptol	99	63	,	,	,
cord-268347-xz6fptol	99	64	but	but	CC
cord-268347-xz6fptol	99	65	not	not	RB
cord-268347-xz6fptol	99	66	ICU	ICU	NNP
cord-268347-xz6fptol	99	67	admission	admission	NN
cord-268347-xz6fptol	99	68	and	and	CC
cord-268347-xz6fptol	99	69	death	death	NN
cord-268347-xz6fptol	99	70	:	:	:
cord-268347-xz6fptol	99	71	real	real	JJ
cord-268347-xz6fptol	99	72	-	-	HYPH
cord-268347-xz6fptol	99	73	life	life	NN
cord-268347-xz6fptol	99	74	data	datum	NNS
cord-268347-xz6fptol	99	75	from	from	IN
cord-268347-xz6fptol	99	76	a	a	DT
cord-268347-xz6fptol	99	77	large	large	JJ
cord-268347-xz6fptol	99	78	cohort	cohort	NN
cord-268347-xz6fptol	99	79	during	during	IN
cord-268347-xz6fptol	99	80	red	red	JJ
cord-268347-xz6fptol	99	81	-	-	HYPH
cord-268347-xz6fptol	99	82	zone	zone	NN
cord-268347-xz6fptol	99	83	declaration	declaration	NN
cord-268347-xz6fptol	99	84	Characteristics	characteristic	NNS
cord-268347-xz6fptol	99	85	associated	associate	VBN
cord-268347-xz6fptol	99	86	with	with	IN
cord-268347-xz6fptol	99	87	hospitalisation	hospitalisation	NN
cord-268347-xz6fptol	99	88	for	for	IN
cord-268347-xz6fptol	99	89	COVID-19	covid-19	NN
cord-268347-xz6fptol	99	90	in	in	IN
cord-268347-xz6fptol	99	91	people	people	NNS
cord-268347-xz6fptol	99	92	with	with	IN
cord-268347-xz6fptol	99	93	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	99	94	disease	disease	NN
cord-268347-xz6fptol	99	95	:	:	:
cord-268347-xz6fptol	99	96	data	datum	NNS
cord-268347-xz6fptol	99	97	from	from	IN
cord-268347-xz6fptol	99	98	the	the	DT
cord-268347-xz6fptol	99	99	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	99	100	Global	Global	NNP
cord-268347-xz6fptol	99	101	Rheumatology	Rheumatology	NNP
cord-268347-xz6fptol	99	102	Alliance	Alliance	NNP
cord-268347-xz6fptol	99	103	physician	physician	NN
cord-268347-xz6fptol	99	104	-	-	HYPH
cord-268347-xz6fptol	99	105	reported	report	VBN
cord-268347-xz6fptol	99	106	registry	registry	NN
cord-268347-xz6fptol	99	107	American	American	NNP
cord-268347-xz6fptol	99	108	College	College	NNP
cord-268347-xz6fptol	99	109	of	of	IN
cord-268347-xz6fptol	99	110	Rheumatology	Rheumatology	NNP
cord-268347-xz6fptol	99	111	guidance	guidance	NN
cord-268347-xz6fptol	99	112	for	for	IN
cord-268347-xz6fptol	99	113	the	the	DT
cord-268347-xz6fptol	99	114	management	management	NN
cord-268347-xz6fptol	99	115	of	of	IN
cord-268347-xz6fptol	99	116	adult	adult	NN
cord-268347-xz6fptol	99	117	patients	patient	NNS
cord-268347-xz6fptol	99	118	with	with	IN
cord-268347-xz6fptol	99	119	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	99	120	disease	disease	NN
cord-268347-xz6fptol	99	121	during	during	IN
cord-268347-xz6fptol	99	122	the	the	DT
cord-268347-xz6fptol	99	123	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	99	124	pandemic	pandemic	NN
cord-268347-xz6fptol	99	125	:	:	:
cord-268347-xz6fptol	99	126	version	version	NN
cord-268347-xz6fptol	99	127	1	1	CD
cord-268347-xz6fptol	99	128	.	.	.
cord-268347-xz6fptol	100	1	Arthritis	Arthritis	NNP
cord-268347-xz6fptol	100	2	Rheumatol	Rheumatol	NNP
cord-268347-xz6fptol	101	1	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	101	2	rapid	rapid	JJ
cord-268347-xz6fptol	101	3	guideline	guideline	NN
cord-268347-xz6fptol	101	4	:	:	:
cord-268347-xz6fptol	101	5	rheumatological	rheumatological	JJ
cord-268347-xz6fptol	101	6	autoimmune	autoimmune	NNP
cord-268347-xz6fptol	101	7	,	,	,
cord-268347-xz6fptol	101	8	inflammatory	inflammatory	JJ
cord-268347-xz6fptol	101	9	and	and	CC
cord-268347-xz6fptol	101	10	metabolic	metabolic	JJ
cord-268347-xz6fptol	101	11	bone	bone	NN
cord-268347-xz6fptol	101	12	disorders	disorder	NNS
cord-268347-xz6fptol	101	13	.	.	.
cord-268347-xz6fptol	102	1	NICE	nice	JJ
cord-268347-xz6fptol	102	2	guideline	guideline	NN
cord-268347-xz6fptol	103	1	Preliminary	preliminary	JJ
cord-268347-xz6fptol	103	2	recommendations	recommendation	NNS
cord-268347-xz6fptol	103	3	of	of	IN
cord-268347-xz6fptol	103	4	the	the	DT
cord-268347-xz6fptol	103	5	German	German	NNP
cord-268347-xz6fptol	103	6	Society	Society	NNP
cord-268347-xz6fptol	103	7	of	of	IN
cord-268347-xz6fptol	103	8	Rheumatology	Rheumatology	NNP
cord-268347-xz6fptol	103	9	(	(	-LRB-
cord-268347-xz6fptol	103	10	DGRh	DGRh	NNP
cord-268347-xz6fptol	103	11	eV	eV	NNP
cord-268347-xz6fptol	103	12	)	)	-RRB-
cord-268347-xz6fptol	103	13	for	for	IN
cord-268347-xz6fptol	103	14	the	the	DT
cord-268347-xz6fptol	103	15	management	management	NN
cord-268347-xz6fptol	103	16	of	of	IN
cord-268347-xz6fptol	103	17	patients	patient	NNS
cord-268347-xz6fptol	103	18	with	with	IN
cord-268347-xz6fptol	103	19	inflammatory	inflammatory	JJ
cord-268347-xz6fptol	103	20	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	103	21	diseases	disease	NNS
cord-268347-xz6fptol	103	22	during	during	IN
cord-268347-xz6fptol	103	23	the	the	DT
cord-268347-xz6fptol	103	24	SARS	SARS	NNP
cord-268347-xz6fptol	103	25	-	-	HYPH
cord-268347-xz6fptol	103	26	CoV-2	CoV-2	NNP
cord-268347-xz6fptol	103	27	/	/	SYM
cord-268347-xz6fptol	103	28	COVID-19	covid-19	VBP
cord-268347-xz6fptol	103	29	pandemic	pandemic	JJ
cord-268347-xz6fptol	103	30	Systemic	systemic	JJ
cord-268347-xz6fptol	103	31	sclerosis	sclerosis	NN
cord-268347-xz6fptol	103	32	and	and	CC
cord-268347-xz6fptol	103	33	the	the	DT
cord-268347-xz6fptol	103	34	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	103	35	pandemic	pandemic	NN
cord-268347-xz6fptol	103	36	:	:	:
cord-268347-xz6fptol	103	37	World	World	NNP
cord-268347-xz6fptol	103	38	Scleroderma	Scleroderma	NNP
cord-268347-xz6fptol	103	39	Foundation	Foundation	NNP
cord-268347-xz6fptol	103	40	preliminary	preliminary	JJ
cord-268347-xz6fptol	103	41	advice	advice	NN
cord-268347-xz6fptol	103	42	for	for	IN
cord-268347-xz6fptol	103	43	patient	patient	JJ
cord-268347-xz6fptol	103	44	management	management	NN
cord-268347-xz6fptol	103	45	EULAR	EULAR	NNP
cord-268347-xz6fptol	103	46	provisional	provisional	JJ
cord-268347-xz6fptol	103	47	recommendations	recommendation	NNS
cord-268347-xz6fptol	103	48	for	for	IN
cord-268347-xz6fptol	103	49	the	the	DT
cord-268347-xz6fptol	103	50	management	management	NN
cord-268347-xz6fptol	103	51	of	of	IN
cord-268347-xz6fptol	103	52	rheumatic	rheumatic	JJ
cord-268347-xz6fptol	103	53	and	and	CC
cord-268347-xz6fptol	103	54	musculoskeletal	musculoskeletal	JJ
cord-268347-xz6fptol	103	55	diseases	disease	NNS
cord-268347-xz6fptol	103	56	in	in	IN
cord-268347-xz6fptol	103	57	the	the	DT
cord-268347-xz6fptol	103	58	context	context	NN
cord-268347-xz6fptol	103	59	of	of	IN
cord-268347-xz6fptol	103	60	SARS	SARS	NNP
cord-268347-xz6fptol	103	61	-	-	HYPH
cord-268347-xz6fptol	103	62	CoV-2	CoV-2	NNP
cord-268347-xz6fptol	103	63	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	103	64	:	:	:
cord-268347-xz6fptol	103	65	consider	consider	VB
cord-268347-xz6fptol	103	66	cytokine	cytokine	JJ
cord-268347-xz6fptol	103	67	storm	storm	NN
cord-268347-xz6fptol	103	68	syndromes	syndrome	NNS
cord-268347-xz6fptol	103	69	and	and	CC
cord-268347-xz6fptol	103	70	immunosuppression	immunosuppression	NN
cord-268347-xz6fptol	103	71	Tocilizumab	tocilizumab	JJ
cord-268347-xz6fptol	103	72	treatment	treatment	NN
cord-268347-xz6fptol	103	73	in	in	IN
cord-268347-xz6fptol	103	74	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	103	75	:	:	:
cord-268347-xz6fptol	103	76	a	a	DT
cord-268347-xz6fptol	103	77	single	single	JJ
cord-268347-xz6fptol	103	78	center	center	NN
cord-268347-xz6fptol	103	79	experience	experience	NN
cord-268347-xz6fptol	103	80	Tocilizumab	Tocilizumab	NNP
cord-268347-xz6fptol	103	81	,	,	,
cord-268347-xz6fptol	103	82	an	an	DT
cord-268347-xz6fptol	103	83	anti	anti	JJ
cord-268347-xz6fptol	103	84	-	-	JJ
cord-268347-xz6fptol	103	85	IL6	il6	JJ
cord-268347-xz6fptol	103	86	receptor	receptor	NN
cord-268347-xz6fptol	103	87	antibody	antibody	NN
cord-268347-xz6fptol	103	88	,	,	,
cord-268347-xz6fptol	103	89	to	to	TO
cord-268347-xz6fptol	103	90	treat	treat	VB
cord-268347-xz6fptol	103	91	COVID-19-related	covid-19-related	JJ
cord-268347-xz6fptol	103	92	respiratory	respiratory	JJ
cord-268347-xz6fptol	103	93	failure	failure	NN
cord-268347-xz6fptol	103	94	:	:	:
cord-268347-xz6fptol	103	95	a	a	DT
cord-268347-xz6fptol	103	96	case	case	NN
cord-268347-xz6fptol	103	97	report	report	NN
cord-268347-xz6fptol	103	98	First	first	JJ
cord-268347-xz6fptol	103	99	case	case	NN
cord-268347-xz6fptol	103	100	of	of	IN
cord-268347-xz6fptol	103	101	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	103	102	in	in	IN
cord-268347-xz6fptol	103	103	a	a	DT
cord-268347-xz6fptol	103	104	patient	patient	NN
cord-268347-xz6fptol	103	105	with	with	IN
cord-268347-xz6fptol	103	106	multiple	multiple	JJ
cord-268347-xz6fptol	103	107	myeloma	myeloma	NN
cord-268347-xz6fptol	103	108	successfully	successfully	RB
cord-268347-xz6fptol	103	109	treated	treat	VBN
cord-268347-xz6fptol	103	110	with	with	IN
cord-268347-xz6fptol	103	111	tocilizumab	tocilizumab	NNP
cord-268347-xz6fptol	103	112	Pilot	Pilot	NNP
cord-268347-xz6fptol	103	113	prospective	prospective	JJ
cord-268347-xz6fptol	103	114	open	open	JJ
cord-268347-xz6fptol	103	115	,	,	,
cord-268347-xz6fptol	104	1	singlearm	singlearm	NNP
cord-268347-xz6fptol	104	2	multicentre	multicentre	NNP
cord-268347-xz6fptol	104	3	study	study	VB
cord-268347-xz6fptol	104	4	on	on	IN
cord-268347-xz6fptol	104	5	off	off	IN
cord-268347-xz6fptol	104	6	-	-	HYPH
cord-268347-xz6fptol	104	7	label	label	NN
cord-268347-xz6fptol	104	8	use	use	NN
cord-268347-xz6fptol	104	9	of	of	IN
cord-268347-xz6fptol	104	10	tocilizumab	tocilizumab	NNP
cord-268347-xz6fptol	104	11	in	in	IN
cord-268347-xz6fptol	104	12	patients	patient	NNS
cord-268347-xz6fptol	104	13	with	with	IN
cord-268347-xz6fptol	104	14	severe	severe	JJ
cord-268347-xz6fptol	104	15	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	104	16	Tocilizumab	Tocilizumab	NNP
cord-268347-xz6fptol	104	17	therapy	therapy	NN
cord-268347-xz6fptol	104	18	reduced	reduce	VBD
cord-268347-xz6fptol	104	19	intensive	intensive	JJ
cord-268347-xz6fptol	104	20	care	care	NN
cord-268347-xz6fptol	104	21	unit	unit	NN
cord-268347-xz6fptol	104	22	admissions	admission	NNS
cord-268347-xz6fptol	104	23	and/or	and/or	CC
cord-268347-xz6fptol	104	24	mortality	mortality	NN
cord-268347-xz6fptol	104	25	in	in	IN
cord-268347-xz6fptol	104	26	COVID-19	covid-19	CD
cord-268347-xz6fptol	104	27	patients	patient	NNS
cord-268347-xz6fptol	105	1	Effective	effective	JJ
cord-268347-xz6fptol	105	2	treatment	treatment	NN
cord-268347-xz6fptol	105	3	of	of	IN
cord-268347-xz6fptol	105	4	severe	severe	JJ
cord-268347-xz6fptol	105	5	COVID-19	covid-19	JJ
cord-268347-xz6fptol	105	6	patients	patient	NNS
cord-268347-xz6fptol	105	7	with	with	IN
cord-268347-xz6fptol	105	8	tocilizumab	tocilizumab	NNP
cord-268347-xz6fptol	105	9	Virological	virological	JJ
cord-268347-xz6fptol	105	10	assessment	assessment	NN
cord-268347-xz6fptol	105	11	of	of	IN
cord-268347-xz6fptol	105	12	hospitalized	hospitalize	VBN
cord-268347-xz6fptol	105	13	patients	patient	NNS
cord-268347-xz6fptol	105	14	with	with	IN
cord-268347-xz6fptol	105	15	COVID-2019	COVID-2019	NNP
cord-268347-xz6fptol	106	1	Predicting	predict	VBG
cord-268347-xz6fptol	106	2	infectious	infectious	JJ
cord-268347-xz6fptol	106	3	SARS	SARS	NNP
cord-268347-xz6fptol	106	4	-	-	HYPH
cord-268347-xz6fptol	106	5	CoV-2	CoV-2	NNP
cord-268347-xz6fptol	106	6	from	from	IN
cord-268347-xz6fptol	106	7	diagnostic	diagnostic	JJ
cord-268347-xz6fptol	106	8	samples	sample	NNS
cord-268347-xz6fptol	107	1	Presymptomatic	Presymptomatic	NNP
cord-268347-xz6fptol	107	2	SARS	SARS	NNP
cord-268347-xz6fptol	107	3	-	-	HYPH
cord-268347-xz6fptol	107	4	CoV-2	CoV-2	NNP
cord-268347-xz6fptol	107	5	infections	infection	NNS
cord-268347-xz6fptol	107	6	and	and	CC
cord-268347-xz6fptol	107	7	transmission	transmission	NN
cord-268347-xz6fptol	107	8	in	in	IN
cord-268347-xz6fptol	107	9	a	a	DT
cord-268347-xz6fptol	107	10	skilled	skilled	JJ
cord-268347-xz6fptol	107	11	nursing	nursing	NN
cord-268347-xz6fptol	107	12	facility	facility	NN
cord-268347-xz6fptol	107	13	Shedding	shedding	NN
cord-268347-xz6fptol	107	14	of	of	IN
cord-268347-xz6fptol	107	15	infectious	infectious	JJ
cord-268347-xz6fptol	107	16	virus	virus	NN
cord-268347-xz6fptol	107	17	in	in	IN
cord-268347-xz6fptol	107	18	hospitalized	hospitalize	VBN
cord-268347-xz6fptol	107	19	patients	patient	NNS
cord-268347-xz6fptol	107	20	with	with	IN
cord-268347-xz6fptol	107	21	coronavirus	coronavirus	NN
cord-268347-xz6fptol	107	22	disease-2019	disease-2019	NNP
cord-268347-xz6fptol	107	23	(	(	-LRB-
cord-268347-xz6fptol	107	24	COVID-19	COVID-19	NNP
cord-268347-xz6fptol	107	25	)	)	-RRB-
cord-268347-xz6fptol	107	26	:	:	:
cord-268347-xz6fptol	108	1	duration	duration	NN
cord-268347-xz6fptol	108	2	and	and	CC
cord-268347-xz6fptol	108	3	key	key	JJ
cord-268347-xz6fptol	108	4	determinants	determinant	NNS
cord-268347-xz6fptol	108	5	.	.	.
cord-268347-xz6fptol	109	1	medRxiv	medRxiv	NNS